



HEALTH ANNUAL STATEMENT

AS OF DECEMBER 31, 2018

OF THE CONDITION AND AFFAIRS OF THE

Aetna Health Inc. (a Maine corporation)

NAIC Group Code 0001 0001 NAIC Company Code 95517 Employer's ID Number 01-0504252
(Current) (Prior)

Organized under the Laws of Maine State of Domicile or Port of Entry ME

Country of Domicile United States of America

Licensed as business type: Health Maintenance Organization

Is HMO Federally Qualified? Yes [] No [X]

Incorporated/Organized 10/03/1995 Commenced Business 04/10/1996

Statutory Home Office 175 Running Hill Road, Suite 301 South Portland, ME, US 04106-3220
(Street and Number) (City or Town, State, Country and Zip Code)

Main Administrative Office 3721 Tecport Drive 800-872-3862
(Street and Number) (Area Code) (Telephone Number)
Harrisburg, PA, US 17111
(City or Town, State, Country and Zip Code)

Mail Address P.O. Box 67103-7103 Harrisburg, PA, US 17106-7103
(Street and Number or P.O. Box) (City or Town, State, Country and Zip Code)

Primary Location of Books and Records 3721 Tecport Drive 800-872-3862
(Street and Number) (Area Code) (Telephone Number)
Harrisburg, PA, US 17111
(City or Town, State, Country and Zip Code)

Internet Website Address www.aetna.com

Statutory Statement Contact Frank Ferris Chronister III 717-541-5742
(Name) (Area Code) (Telephone Number)
StatutoryReporting@aetna.com 717-526-2888
(E-mail Address) (FAX Number)

OFFICERS

President Mark Costa Santos Principal Financial Officer and Controller Steven Matthew Conte #
 Vice President and Secretary Edward Chung-I Lee

OTHER

Kevin James Casey, Senior Investment Officer John Patrick Maroney, Vice President and Treasurer
Gregory Stephen Martino, Vice President Cara Sue Mullen, Assistant Controller #

DIRECTORS OR TRUSTEES

Louise Alta McCleery Spence William Papke # Mark Costa Santos

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

Mark Costa Santos
 President

Edward Chung-I Lee
 Vice President and Secretary

Steven Matthew Conte
 Principal Financial Officer and Controller

State of..... Connecticut
 County of..... Hartford

Subscribed and sworn to before me this

1st day of February, 2019

State of..... Connecticut
 County of..... Hartford

Subscribed and sworn to before me this

14 day of February, 2019

State of..... Pennsylvania
 County of..... Montgomery

Subscribed and sworn to before me this

14th day of February, 2019

ASSETS

	Current Year			Prior Year
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1. Bonds (Schedule D)	27,575,449		27,575,449	24,939,445
2. Stocks (Schedule D):				
2.1 Preferred stocks			0	0
2.2 Common stocks			0	0
3. Mortgage loans on real estate (Schedule B):				
3.1 First liens			0	
3.2 Other than first liens			0	
4. Real estate (Schedule A):				
4.1 Properties occupied by the company (less \$			0	
encumbrances)				
4.2 Properties held for the production of income (less				
\$ encumbrances)			0	
4.3 Properties held for sale (less \$				
encumbrances)			0	
5. Cash (\$0 , Schedule E - Part 1), cash equivalents				
(\$5,677,469 , Schedule E - Part 2) and short-term				
investments (\$0 , Schedule DA)	5,677,469		5,677,469	18,485
6. Contract loans, (including \$ premium notes)			0	
7. Derivatives (Schedule DB)			0	0
8. Other invested assets (Schedule BA)	0		0	0
9. Receivables for securities			0	
10. Securities lending reinvested collateral assets (Schedule DL)			0	0
11. Aggregate write-ins for invested assets	0	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	33,252,918	0	33,252,918	24,957,930
13. Title plants less \$ charged off (for Title insurers				
only)			0	
14. Investment income due and accrued	153,609	0	153,609	102,837
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection	2,411,055	126,069	2,284,986	2,190,164
15.2 Deferred premiums and agents' balances and installments booked but				
deferred and not yet due (including \$				
earned but unbilled premiums)			0	
15.3 Accrued retrospective premiums (\$154) and				
contracts subject to redetermination (\$)	154	0	154	502,677
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers	527	0	527	15,734
16.2 Funds held by or deposited with reinsured companies			0	
16.3 Other amounts receivable under reinsurance contracts			0	
17. Amounts receivable relating to uninsured plans	485,680	0	485,680	117,883
18.1 Current federal and foreign income tax recoverable and interest thereon			0	380,345
18.2 Net deferred tax asset		0	0	92,581
19. Guaranty funds receivable or on deposit			0	
20. Electronic data processing equipment and software			0	
21. Furniture and equipment, including health care delivery assets				
(\$)			0	
22. Net adjustment in assets and liabilities due to foreign exchange rates			0	
23. Receivables from parent, subsidiaries and affiliates	0		0	
24. Health care (\$492,549) and other amounts receivable	492,549	0	492,549	267,843
25. Aggregate write-ins for other than invested assets	573,548	0	573,548	233,184
26. Total assets excluding Separate Accounts, Segregated Accounts and				
Protected Cell Accounts (Lines 12 to 25)	37,370,040	126,069	37,243,971	28,861,178
27. From Separate Accounts, Segregated Accounts and Protected Cell				
Accounts			0	
28. Total (Lines 26 and 27)	37,370,040	126,069	37,243,971	28,861,178
DETAILS OF WRITE-INS				
1101.				
1102.				
1103.				
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501. Current State Income Tax Receivable	573,548	0	573,548	233,184
2502.				
2503.				
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	573,548	0	573,548	233,184

LIABILITIES, CAPITAL AND SURPLUS

	Current Year			Prior Year
	1	2	3	4
	Covered	Uncovered	Total	Total
1. Claims unpaid (less \$18,928 reinsurance ceded)	3,970,479	102,930	4,073,409	5,980,497
2. Accrued medical incentive pool and bonus amounts	1,452,537		1,452,537	1,945,005
3. Unpaid claims adjustment expenses.....	57,974		57,974	88,616
4. Aggregate health policy reserves, including the liability of \$1,320,783 for medical loss ratio rebate per the Public Health Service Act	3,375,289		3,375,289	2,182,405
5. Aggregate life policy reserves.....			0	
6. Property/casualty unearned premium reserves.....			0	
7. Aggregate health claim reserves.....	15,846		15,846	39,111
8. Premiums received in advance.....	12,138		12,138	26,921
9. General expenses due or accrued.....	17,069		17,069	26,761
10.1 Current federal and foreign income tax payable and interest thereon (including \$ on realized capital gains (losses))	1,144		1,144	0
10.2 Net deferred tax liability.....	25,047		25,047	
11. Ceded reinsurance premiums payable.....			0	
12. Amounts withheld or retained for the account of others.....			0	
13. Remittances and items not allocated.....			0	
14. Borrowed money (including \$ current) and interest thereon \$ (including \$ current).....			0	
15. Amounts due to parent, subsidiaries and affiliates.....	5,585,165		5,585,165	677,428
16. Derivatives.....			0	
17. Payable for securities.....			0	
18. Payable for securities lending			0	
19. Funds held under reinsurance treaties (with \$ authorized reinsurers, \$23,604 unauthorized reinsurers and \$0 certified reinsurers).....	23,604		23,604	48,534
20. Reinsurance in unauthorized and certified (\$) companies			0	
21. Net adjustments in assets and liabilities due to foreign exchange rates			0	
22. Liability for amounts held under uninsured plans.....	28,875		28,875	298,744
23. Aggregate write-ins for other liabilities (including \$ current).....	0	0	0	0
24. Total liabilities (Lines 1 to 23).....	14,565,167	102,930	14,668,097	11,314,022
25. Aggregate write-ins for special surplus funds.....	XXX	XXX	0	1,564,000
26. Common capital stock.....	XXX	XXX	1,000,000	1,000,000
27. Preferred capital stock.....	XXX	XXX		
28. Gross paid in and contributed surplus.....	XXX	XXX	8,700,000	8,700,000
29. Surplus notes.....	XXX	XXX		0
30. Aggregate write-ins for other than special surplus funds.....	XXX	XXX	0	0
31. Unassigned funds (surplus).....	XXX	XXX	12,875,874	6,283,156
32. Less treasury stock, at cost:				
32.1 shares common (value included in Line 26 \$).....	XXX	XXX		
32.2 shares preferred (value included in Line 27 \$).....	XXX	XXX		
33. Total capital and surplus (Lines 25 to 31 minus Line 32).....	XXX	XXX	22,575,874	17,547,156
34. Total liabilities, capital and surplus (Lines 24 and 33).....	XXX	XXX	37,243,971	28,861,178
DETAILS OF WRITE-INS				
2301. 0	0	0	0	0
2302. 0	0	0	0	0
2303. 0	0	0	0	0
2398. Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399. Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above).....	0	0	0	0
2501. Estimated Health Insurer Fee	XXX	XXX	0	1,564,000
2502. 0	XXX	XXX	0	0
2503. 0	XXX	XXX	0	0
2598. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above).....	XXX	XXX	0	1,564,000
3001. 0	XXX	XXX	0	0
3002. 0	XXX	XXX	0	0
3003. 0	XXX	XXX	0	0
3098. Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099. Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above).....	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	Current Year		Prior Year
	1 Uncovered	2 Total	3 Total
1. Member Months.....	XXX	104,140	133,929
2. Net premium income (including \$ non-health premium income)	XXX	66,905,379	79,027,743
3. Change in unearned premium reserves and reserve for rate credits	XXX	(87,316)	(1,221,117)
4. Fee-for-service (net of \$ medical expenses)	XXX	0	0
5. Risk revenue	XXX	0	0
6. Aggregate write-ins for other health care related revenues	XXX	0	0
7. Aggregate write-ins for other non-health revenues	XXX	0	0
8. Total revenues (Lines 2 to 7)	XXX	66,818,063	77,806,626
Hospital and Medical:			
9. Hospital/medical benefits	636,131	39,327,506	46,450,140
10. Other professional services	0	0	0
11. Outside referrals	624,994	624,994	1,106,074
12. Emergency room and out-of-area	83,010	2,618,603	3,158,478
13. Prescription drugs	121,121	6,851,285	10,338,525
14. Aggregate write-ins for other hospital and medical	0	0	0
15. Incentive pool, withhold adjustments and bonus amounts		726,189	621,721
16. Subtotal (Lines 9 to 15)	1,465,256	50,148,577	61,674,938
Less:			
17. Net reinsurance recoveries		260,763	274,148
18. Total hospital and medical (Lines 16 minus 17)	1,465,256	49,887,814	61,400,790
19. Non-health claims (net)			0
20. Claims adjustment expenses, including \$ 899,928 cost containment expenses		1,318,543	1,308,288
21. General administrative expenses		9,390,154	9,311,687
22. Increase in reserves for life and accident and health contracts (including \$ increase in reserves for life only)		0	0
23. Total underwriting deductions (Lines 18 through 22).....	1,465,256	60,596,511	72,020,765
24. Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	6,221,552	5,785,861
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)		710,846	589,771
26. Net realized capital gains (losses) less capital gains tax of \$ (55,750)		(1,013)	13,789
27. Net investment gains (losses) (Lines 25 plus 26)	0	709,833	603,560
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$) (amount charged off \$)]			
29. Aggregate write-ins for other income or expenses	0	0	0
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	6,931,385	6,389,421
31. Federal and foreign income taxes incurred	XXX	1,683,679	1,800,566
32. Net income (loss) (Lines 30 minus 31)	XXX	5,247,706	4,588,855
DETAILS OF WRITE-INS			
0601. 0	XXX	0	0
0602. 0	XXX	0	0
0603. 0	XXX	0	0
0698. Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701. 0	XXX	0	0
0702. 0	XXX	0	0
0703. 0	XXX	0	0
0798. Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401. 0	0	0	0
1402. 0	0	0	0
1403. 0	0	0	0
1498. Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901. 0	0	0	0
2902. 0	0	0	0
2903. 0	0	0	0
2998. Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999. Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	0	0

STATEMENT OF REVENUE AND EXPENSES (Continued)

	1 Current Year	2 Prior Year
CAPITAL AND SURPLUS ACCOUNT		
33. Capital and surplus prior reporting year.....	17,547,156	15,522,822
34. Net income or (loss) from Line 32	5,247,706	4,588,855
35. Change in valuation basis of aggregate policy and claim reserves		
36. Change in net unrealized capital gains (losses) less capital gains tax of \$0		
37. Change in net unrealized foreign exchange capital gain or (loss)		
38. Change in net deferred income tax	(117,629)	(115,623)
39. Change in nonadmitted assets	(101,359)	1,102
40. Change in unauthorized and certified reinsurance	0	0
41. Change in treasury stock	0	0
42. Change in surplus notes	0	0
43. Cumulative effect of changes in accounting principles.....		
44. Capital Changes:		
44.1 Paid in	0	0
44.2 Transferred from surplus (Stock Dividend).....	0	
44.3 Transferred to surplus.....		
45. Surplus adjustments:		
45.1 Paid in	0	0
45.2 Transferred to capital (Stock Dividend)		
45.3 Transferred from capital		
46. Dividends to stockholders		(2,450,000)
47. Aggregate write-ins for gains or (losses) in surplus	0	0
48. Net change in capital and surplus (Lines 34 to 47)	5,028,718	2,024,334
49. Capital and surplus end of reporting period (Line 33 plus 48)	22,575,874	17,547,156
DETAILS OF WRITE-INS		
4701. 0	0	0
4702. 0	0	0
4703. 0	0	0
4798. Summary of remaining write-ins for Line 47 from overflow page	0	0
4799. Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

	1	2
	Current Year	Prior Year
Cash from Operations		
1. Premiums collected net of reinsurance	68,302,506	77,802,070
2. Net investment income	563,041	463,172
3. Miscellaneous income	0	0
4. Total (Lines 1 through 3)	68,865,547	78,265,242
5. Benefit and loss related payments	52,520,134	61,880,652
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7. Commissions, expenses paid and aggregate write-ins for deductions	11,727,061	11,189,795
8. Dividends paid to policyholders		
9. Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)	1,246,441	1,562,486
10. Total (Lines 5 through 9)	65,493,636	74,632,933
11. Net cash from operations (Line 4 minus Line 10)	3,371,911	3,632,309
Cash from Investments		
12. Proceeds from investments sold, matured or repaid:		
12.1 Bonds	11,248,394	2,397,018
12.2 Stocks	0	0
12.3 Mortgage loans	0	0
12.4 Real estate	0	0
12.5 Other invested assets	0	0
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	(34)	(49)
12.7 Miscellaneous proceeds	0	0
12.8 Total investment proceeds (Lines 12.1 to 12.7)	11,248,360	2,396,969
13. Cost of investments acquired (long-term only):		
13.1 Bonds	13,844,095	6,493,495
13.2 Stocks	0	0
13.3 Mortgage loans	0	0
13.4 Real estate	0	0
13.5 Other invested assets	0	0
13.6 Miscellaneous applications	0	0
13.7 Total investments acquired (Lines 13.1 to 13.6)	13,844,095	6,493,495
14. Net increase (decrease) in contract loans and premium notes	0	0
15. Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(2,595,735)	(4,096,526)
Cash from Financing and Miscellaneous Sources		
16. Cash provided (applied):		
16.1 Surplus notes, capital notes	0	0
16.2 Capital and paid in surplus, less treasury stock	0	0
16.3 Borrowed funds	0	0
16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
16.5 Dividends to stockholders	0	2,450,000
16.6 Other cash provided (applied)	4,882,808	(681,458)
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	4,882,808	(3,131,458)
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	5,658,984	(3,595,675)
19. Cash, cash equivalents and short-term investments:		
19.1 Beginning of year	18,485	3,614,160
19.2 End of year (Line 18 plus Line 19.1)	5,677,469	18,485

Note: Supplemental disclosures of cash flow information for non-cash transactions:

--	--	--

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

2

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical)	13,097,940			13,097,940
2. Medicare Supplement				0
3. Dental only				0
4. Vision only				0
5. Federal Employees Health Benefits Plan	0			0
6. Title XVIII - Medicare	54,017,456		210,016	53,807,440
7. Title XIX - Medicaid	0			0
8. Other health				0
9. Health subtotal (Lines 1 through 8)	67,115,396	0	210,016	66,905,380
10. Life	0			0
11. Property/casualty	0			0
12. Totals (Lines 9 to 11)	67,115,396	0	210,016	66,905,380

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1. Payments during the year:										
1.1 Direct	51,596,656	11,018,945	0	0	0	0	40,577,711	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	295,179	15,207	0	0	0	0	279,972	0	0	0
1.4 Net	51,301,477	11,003,738	0	0	0	0	40,297,739	0	0	0
2. Paid medical incentive pools and bonuses	1,218,658	107,573	0	0	0	0	1,111,085	0	0	0
3. Claim liability December 31, current year from Part 2A:										
3.1 Direct	4,092,337	1,103,291	0	0	0	0	2,989,046	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	18,928	0	0	0	0	0	18,928	0	0	0
3.4 Net	4,073,409	1,103,291	0	0	0	0	2,970,118	0	0	0
4. Claim reserve December 31, current year from Part 2D:										
4.1 Direct	15,846	15,846	0	0	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	15,846	15,846	0	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current year	1,452,537	4,486	0	0	0	0	1,448,051	0	0	0
6. Net healthcare receivables (a)	224,706	(14,156)	0	0	0	0	238,862	0	0	0
7. Amounts recoverable from reinsurers December 31, current year	527	527	0	0	0	0	0	0	0	0
8. Claim liability December 31, prior year from Part 2A:										
8.1 Direct	6,018,634	2,808,125	0	0	0	0	3,210,509	0	0	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	38,137	0	0	0	0	0	38,137	0	0	0
8.4 Net	5,980,497	2,808,125	0	0	0	0	3,172,372	0	0	0
9. Claim reserve December 31, prior year from Part 2D:										
9.1 Direct	39,111	39,111								
9.2 Reinsurance assumed	0									
9.3 Reinsurance ceded	0									
9.4 Net	39,111	39,111	0	0	0	0	0	0	0	0
10. Accrued medical incentive pools and bonuses, prior year	1,945,005	122					1,944,883			
11. Amounts recoverable from reinsurers December 31, prior year	15,734	15,734								
12. Incurred Benefits:										
12.1 Direct	49,422,388	9,305,002	0	0	0	0	40,117,386	0	0	0
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
12.3 Reinsurance ceded	260,763	0	0	0	0	0	260,763	0	0	0
12.4 Net	49,161,625	9,305,002	0	0	0	0	39,856,623	0	0	0
13. Incurred medical incentive pools and bonuses	726,190	111,937	0	0	0	0	614,253	0	0	0

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1. Reported in Process of Adjustment:										
1.1 Direct	730,710	319,984	0	0	0	0	410,726	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	730,710	319,984	0	0	0	0	410,726	0	0	0
2. Incurred but Unreported:										
2.1 Direct	3,361,627	783,307	0	0	0	0	2,578,320	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	18,928	0	0	0	0	0	18,928	0	0	0
2.4 Net	3,342,699	783,307	0	0	0	0	2,559,392	0	0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0	0	0	0	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct	4,092,337	1,103,291	0	0	0	0	2,989,046	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	18,928	0	0	0	0	0	18,928	0	0	0
4.4 Net	4,073,409	1,103,291	0	0	0	0	2,970,118	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

Line of Business	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5	6
	1	2	3	4		
	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical)	1,516,909	9,502,036	61,705	1,057,432	1,578,614	2,847,236
2. Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare	2,390,375	37,907,364	42,078	2,928,040	2,432,453	3,172,372
7. Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)	3,907,284	47,409,400	103,783	3,985,472	4,011,067	6,019,608
10. Healthcare receivables (a)	0	492,549	0	0	0	267,843
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts	0	1,218,657	452,572	999,965	452,572	1,945,005
13. Totals (Lines 9 - 10 + 11 + 12)	3,907,284	48,135,508	556,355	4,985,437	4,463,639	7,696,770

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	5,078	5,209	5,197	5,141	5,141
2.	2014	32,548	35,606	35,541	35,536	35,536
3.	2015	XXX	16,695	18,807	18,793	18,793
4.	2016	XXX	XXX	14,820	16,974	16,974
5.	2017	XXX	XXX	XXX	18,929	20,446
6.	2018	XXX	XXX	XXX	XXX	9,578

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	5,160	5,251	5,210	5,141	5,141
2.	2014	35,153	35,637	35,556	35,545	35,545
3.	2015	XXX	18,921	18,822	18,800	18,800
4.	2016	XXX	XXX	17,382	17,008	17,008
5.	2017	XXX	XXX	XXX	21,726	23,305
6.	2018	XXX	XXX	XXX	XXX	10,640

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

Years in which Premiums were Earned and Claims were Incurred		1	2	3	4	5	6	7	8	9	10
		Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2014	42,959	35,536	0	0.0	35,536	82.7	0	0	35,536	82.7
2.	2015	22,277	18,793	0	0.0	18,793	84.4	0	0	18,793	84.4
3.	2016	19,810	16,974	0	0.0	16,974	85.7	0	0	16,974	85.7
4.	2017	23,844	20,446	0	0.0	20,446	85.7	62	0	20,508	86.0
5.	2018	13,092	9,578	249	2.6	9,827	75.1	1,062	19	10,908	83.3

Section A - Paid Health Claims - Medicare Supplement

NONE

NONE

NONE

NONE

NONE

12.D0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Dental Only

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section B - Incurred Health Claims - Dental Only

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Incurred	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2014			NONE							
2. 2015										
3. 2016										
4. 2017										
5. 2018										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Vision Only

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section B - Incurred Health Claims - Vision Only

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Incurred	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2014			NONE							
2. 2015										
3. 2016										
4. 2017										
5. 2018										

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

NONE

NONE

NONE

NONE

NONE

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	2,725	2,672	2,624	2,620	2,620
2.	2014	52,398	56,414	56,321	56,279	56,279
3.	2015	XXX	44,250	48,243	48,212	48,212
4.	2016	XXX	XXX	41,985	45,563	45,563
5.	2017	XXX	XXX	XXX	37,119	39,509
6.	2018	XXX	XXX	XXX	XXX	38,557

Section B - Incurred Health Claims - Title XVIII

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	2,818	2,717	2,633	2,620	2,620
2.	2014	57,225	56,644	56,337	56,292	56,292
3.	2015	XXX	50,085	48,338	48,229	48,229
4.	2016	XXX	XXX	47,736	45,839	45,839
5.	2017	XXX	XXX	XXX	41,930	44,815
6.	2018	XXX	XXX	XXX	XXX	42,481

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

Years in which Premiums were Earned and Claims were Incurred		1	2	3	4	5	6	7	8	9	10
		Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Unpaid Claims Adjustment Expenses	Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2014	61,758	56,279	0	0.0	56,279	91.1	0	0	56,279	91.1
2.	2015	57,807	48,212	0	0.0	48,212	83.4	0	0	48,212	83.4
3.	2016	55,471	45,563	0	0.0	45,563	82.1	0	0	45,563	82.1
4.	2017	53,963	39,509	0	0.0	39,509	73.2	495	0	40,004	74.1
5.	2018	53,936	38,557	1,070	2.8	39,627	73.5	3,924	39	43,590	80.8

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Title XIX

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section B - Incurred Health Claims - Title XIX

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Incurred (Col. 3/2)	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 4+3) Percent	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2014			NONE							
2. 2015										
3. 2016										
4. 2017										
5. 2018										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Other

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section B - Incurred Health Claims - Other

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	NONE				
2.	2014					
3.	2015		XXX			
4.	2016		XXX	XXX		
5.	2017		XXX	XXX	XXX	
6.	2018		XXX	XXX	XXX	XXX

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Incurred (Col. 3/2)	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 4+3) Percent	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2014			NONE							
2. 2015										
3. 2016										
4. 2017										
5. 2018										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Grand Total

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	7,803	7,881	7,821	7,761	7,761
2.	2014	84,946	92,020	91,862	91,815	91,815
3.	2015	XXX	60,945	67,050	67,005	67,005
4.	2016	XXX	XXX	56,805	62,537	62,537
5.	2017	XXX	XXX	XXX	56,048	59,955
6.	2018	XXX	XXX	XXX	XXX	48,135

Section B - Incurred Health Claims - Grand Total

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2014	2 2015	3 2016	4 2017	5 2018
1.	Prior	7,978	7,968	7,843	7,761	7,761
2.	2014	92,378	92,281	91,893	91,837	91,837
3.	2015	XXX	69,006	67,160	67,029	67,029
4.	2016	XXX	XXX	65,118	62,847	62,847
5.	2017	XXX	XXX	XXX	63,656	68,120
6.	2018	XXX	XXX	XXX	XXX	53,121

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2014	104,717	91,815	0	0.0	91,815	87.7	0	0	91,815	87.7
2. 2015	80,084	67,005	0	0.0	67,005	83.7	0	0	67,005	83.7
3. 2016	75,281	62,537	0	0.0	62,537	83.1	0	0	62,537	83.1
4. 2017	77,807	59,955	0	0.0	59,955	77.1	557	0	60,512	77.8
5. 2018	67,028	48,135	1,319	2.7	49,454	73.8	4,986	58	54,498	81.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	2	3	4	5	6	7	8	9
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other
1. Unearned premium reserves	0								
2. Additional policy reserves (a)	0								
3. Reserve for future contingent benefits	0								
4. Reserve for rate credits or experience rating refunds (including \$) for investment income	3,375,289	375,695					2,999,594		
5. Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	0
6. Totals (gross)	3,375,289	375,695	0	0	0	0	2,999,594	0	0
7. Reinsurance ceded	0								
8. Totals (Net)(Page 3, Line 4)	3,375,289	375,695	0	0	0	0	2,999,594	0	0
9. Present value of amounts not yet due on claims	0								
10. Reserve for future contingent benefits	15,846	15,846							
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12. Totals (gross)	15,846	15,846	0	0	0	0	0	0	0
13. Reinsurance ceded	0								
14. Totals (Net)(Page 3, Line 7)	15,846	15,846	0	0	0	0	0	0	0
DETAILS OF WRITE-INS									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page.....	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0

(a) Includes \$ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

	Claim Adjustment Expenses		3	4	5
	1	2			
	Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1. Rent (\$ for occupancy of own building)	26,096	7,749	39,792	1,215	74,852
2. Salary, wages and other benefits	720,053	252,123	2,573,320	21,719	3,567,215
3. Commissions (less \$ ceded plus \$ assumed)			1,374,368		1,374,368
4. Legal fees and expenses			59,318	24	59,342
5. Certifications and accreditation fees					0
6. Auditing, actuarial and other consulting services		58,852	835,301	8,409	902,562
7. Traveling expenses	3,735	882	88,062	362	93,041
8. Marketing and advertising	(398)	7,519	201,209		208,330
9. Postage, express and telephone	9,478	31,012	159,606	247	200,343
10. Printing and office supplies		5,396	78,874	46	84,316
11. Occupancy, depreciation and amortization	13,671	5,153	(18,823)		1
12. Equipment		(3,913)	133,249	702	130,038
13. Cost or depreciation of EDP equipment and software	23	11,976	229,934	496	242,429
14. Outsourced services including EDP, claims, and other services	69,099	20,416	1,246,834	3,238	1,339,587
15. Boards, bureaus and association fees	60	118	6,946	20	7,144
16. Insurance, except on real estate	2,026	758	72,126	18	74,928
17. Collection and bank service charges	0	587	4,389	2,371	7,347
18. Group service and administration fees					0
19. Reimbursements by uninsured plans					0
20. Reimbursements from fiscal intermediaries					0
21. Real estate expenses	34	127	55,233	9	55,403
22. Real estate taxes	167		10,527		10,694
23. Taxes, licenses and fees:					
23.1 State and local insurance taxes			123,104		123,104
23.2 State premium taxes					0
23.3 Regulatory authority licenses and fees			18,198		18,198
23.4 Payroll taxes	55,031	19,269	197,937	1,889	274,126
23.5 Other (excluding federal income and real estate taxes)			1,569,689		1,569,689
24. Investment expenses not included elsewhere					0
25. Aggregate write-ins for expenses	853	592	330,961	0	332,406
26. Total expenses incurred (Lines 1 to 25)	899,928	418,616	9,390,154	40,765	(a)10,749,463
27. Less expenses unpaid December 31, current year ..	39,568	18,406	17,069		75,043
28. Add expenses unpaid December 31, prior year	75,465	13,151	26,761	0	115,377
29. Amounts receivable relating to uninsured plans, prior year	0	0	117,883	0	117,883
30. Amounts receivable relating to uninsured plans, current year			485,680		485,680
31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	935,825	413,361	9,767,643	40,765	11,157,594
DETAILS OF WRITE-INS					
2501. Miscellaneous	853	(317)	(40,297)		(39,761)
2502. Loss adjustment expense			(30,642)		(30,642)
2503. Rx rebate expense			407,892		407,892
2598. Summary of remaining write-ins for Line 25 from overflow page	0	909	(5,992)	0	(5,083)
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	853	592	330,961	0	332,406

(a) Includes management fees of \$9,016,460 to affiliates and \$ to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds	(a)296,399269,060
1.1	Bonds exempt from U.S. tax	(a)
1.2	Other bonds (unaffiliated)	(a)343,065421,170
1.3	Bonds of affiliates	(a)
2.1	Preferred stocks (unaffiliated)	(b)
2.11	Preferred stocks of affiliates	(b)
2.2	Common stocks (unaffiliated)
2.21	Common stocks of affiliates
3.	Mortgage loans	(c)
4.	Real estate	(d)
5	Contract Loans
6	Cash, cash equivalents and short-term investments	(e)61,34961,349
7	Derivative instruments	(f)
8.	Other invested assets
9.	Aggregate write-ins for investment income3030
10.	Total gross investment income	700,843	751,609
11.	Investment expenses		(g)38,876
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)1,889
13.	Interest expense		(h)
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income0
16.	Total deductions (Lines 11 through 15)40,765
17.	Net investment income (Line 10 minus Line 16)		710,844
DETAILS OF WRITE-INS			
0901.	Misc Sec Lending3030
0902.
0903.
0998.	Summary of remaining write-ins for Line 9 from overflow page00
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	30	30
1501.
1502.
1503.
1598.	Summary of remaining write-ins for Line 15 from overflow page0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

- (a) Includes \$99,807 accrual of discount less \$2,774 amortization of premium and less \$47,383 paid for accrued interest on purchases.
- (b) Includes \$ accrual of discount less \$ amortization of premium and less \$ paid for accrued dividends on purchases.
- (c) Includes \$ accrual of discount less \$ amortization of premium and less \$ paid for accrued interest on purchases.
- (d) Includes \$ for company's occupancy of its own buildings; and excludes \$ interest on encumbrances.
- (e) Includes \$61,043 accrual of discount less \$ amortization of premium and less \$ paid for accrued interest on purchases.
- (f) Includes \$ accrual of discount less \$ amortization of premium.
- (g) Includes \$.40,763 investment expenses and \$ investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.
- (h) Includes \$ interest on surplus notes and \$ interest on capital notes.
- (i) Includes \$ depreciation on real estate and \$ depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	3	4	5
		Realized Gain (Loss) On Sales or Maturity	Other Realized Adjustments	Total Realized Capital Gain (Loss) (Columns 1 + 2)	Change in Unrealized Capital Gain (Loss)	Change in Unrealized Foreign Exchange Capital Gain (Loss)
1.	U.S. Government bonds	34,867	(26,669)	8,198	0	0
1.1	Bonds exempt from U.S. tax	0
1.2	Other bonds (unaffiliated)	(64,928)	0	(64,928)	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0
4.	Real estate	0	0	0
5.	Contract loans	0
6.	Cash, cash equivalents and short-term investments	(34)	(34)
7.	Derivative instruments	0
8.	Other invested assets	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(30,095)	(26,669)	(56,764)	0	0
DETAILS OF WRITE-INS						
0901.
0902.
0903.
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

	1	2	3
	Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1. Bonds (Schedule D)		0	0
2. Stocks (Schedule D):			
2.1 Preferred stocks		0	0
2.2 Common stocks		0	0
3. Mortgage loans on real estate (Schedule B):			
3.1 First liens			0
3.2 Other than first liens.....			0
4. Real estate (Schedule A):			
4.1 Properties occupied by the company			0
4.2 Properties held for the production of income.....			0
4.3 Properties held for sale			0
5. Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			0
6. Contract loans			0
7. Derivatives (Schedule DB)		0	0
8. Other invested assets (Schedule BA)			0
9. Receivables for securities			0
10. Securities lending reinvested collateral assets (Schedule DL)		0	0
11. Aggregate write-ins for invested assets	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13. Title plants (for Title insurers only)			0
14. Investment income due and accrued	0	0	0
15. Premiums and considerations:			
15.1 Uncollected premiums and agents' balances in the course of collection	126,069	24,710	(101,359)
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			0
15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16. Reinsurance:			
16.1 Amounts recoverable from reinsurers	0	0	0
16.2 Funds held by or deposited with reinsured companies			0
16.3 Other amounts receivable under reinsurance contracts			0
17. Amounts receivable relating to uninsured plans	0	0	0
18.1 Current federal and foreign income tax recoverable and interest thereon		0	0
18.2 Net deferred tax asset	0	0	0
19. Guaranty funds receivable or on deposit			0
20. Electronic data processing equipment and software			0
21. Furniture and equipment, including health care delivery assets			0
22. Net adjustment in assets and liabilities due to foreign exchange rates			0
23. Receivable from parent, subsidiaries and affiliates			0
24. Health care and other amounts receivable	0	0	0
25. Aggregate write-ins for other than invested assets	0	0	0
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	126,069	24,710	(101,359)
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0
28. Total (Lines 26 and 27)	126,069	24,710	(101,359)
DETAILS OF WRITE-INS			
1101.			
1102.			
1103.			
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.			
2502.			
2503.			
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	0	0	0

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

Source of Enrollment	Total Members at End of					6 Current Year Member Months
	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	
1. Health Maintenance Organizations	10,734	8,869	8,642	8,415	8,265	103,455
2. Provider Service Organizations						
3. Preferred Provider Organizations						
4. Point of Service	433	119	35	35	32	685
5. Indemnity Only						
6. Aggregate write-ins for other lines of business.....	0	0	0	0	0	0
7. Total	11,167	8,988	8,677	8,450	8,297	104,140
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

NOTES TO FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying statutory financial statements of Aetna Health Inc. (a Maine corporation) (the “Company”), indirectly a wholly-owned subsidiary of CVS Health Corporation (“CVS Health”), have been prepared in conformity with accounting practices prescribed or permitted by the Maine Department of Professional and Financial Regulation, Bureau of Insurance (“Maine Department”) (“Maine Accounting Practices”). The Maine Department recognizes only statutory accounting practices prescribed or permitted by the State of Maine for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners’ (“NAIC”) *Accounting Practices and Procedures Manual* (“NAIC SAP”). On November 28, 2018, CVS Health acquired Aetna Inc. (“Aetna”) and at that date became the Company’s ultimate parent (the “Aetna Acquisition”).

A reconciliation of the Company’s net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of Maine for the years ending December 31, 2018 and 2017 is as follows:

	SSAP #	F/S Page	F/S Line #	2018	2017
NET INCOME					
(1) State basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$5,247,706	\$4,588,855
(2) State Prescribed Practices that increase/(decrease) NAIC SAP:					
(3) State Permitted Practices that increase/(decrease) NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$5,247,706	\$4,588,855
SURPLUS					
(5) State basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$22,575,874	\$17,547,156
(6) State Prescribed Practices that increase/(decrease) NAIC SAP:					
(7) State Permitted Practices that increase/(decrease) NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$22,575,874	\$17,547,156

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these financial statements in conformity with Maine Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

C. Accounting Policies

The Company applies the following significant accounting policies:

(1) Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value. Cash accounts with positive balances shall not be reported separately from cash accounts with negative balances. If in the aggregate, the reporting entity has a net negative cash balance, it shall be reported as a negative asset and shall not be recorded as a liability.

(2) Bonds

Bonds, which include special deposits, are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company estimates fair values using valuation methodologies based on available and observable market information or by using a matrix pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2018 and 2017. Bonds include all investments whose maturity is greater than one year when purchased. Loan-backed and structured securities are carried at amortized cost adjusted for unamortized premiums and discounts. Premiums and discounts on loan-backed and structured securities are amortized using the interest method over the estimated remaining term of the securities, adjusted for anticipated prepayments. All adjustments between amortized cost and carrying value are reflected in unrealized capital gains and losses and are reported as direct adjustments to surplus. Bonds are recorded as purchases or sales on the trade date.

The Company periodically reviews its bonds to determine whether a decline in fair value below the carrying value is other-than-temporary. For bonds, other than loan-backed and structured securities, an other-than-temporary impairment ("OTTI") shall be recorded if it is probable that the Company will be unable to collect all amounts due according to the contractual terms in effect at the date of acquisition. Declines deemed to be OTTI in the cost basis are recognized as realized capital losses. Yield-related impairments are deemed other-than-temporary when the Company intends to sell an investment at the reporting date before recovery of the cost of the investment.

For loan-backed and structured securities, the Company records OTTI when the fair value of the loan-backed or structured security is less than the amortized cost basis at the balance sheet date and (1) the Company intends to sell the investment, or (2) the Company does not have the intent and ability to retain the investment for the time sufficient to recover the amortized cost basis, or (3) the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security and has the intent and ability to hold. If it is determined an OTTI has occurred because of (1) or (2), the amount of the OTTI is equal to the difference between the amortized cost and the fair value of the security at the balance sheet date and this difference is recorded as a realized capital loss. If it is determined an OTTI has occurred because of (3), the amount of the OTTI is equal to the difference between the amortized cost and the present value of cash flows expected to be collected, discounted at the loan-backed or structured security's effective interest rate and this difference is also accounted for as a realized capital loss.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-than-temporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from the Company's expectations and the risk that facts and circumstances factored into its assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

- (3) The Company did not own any common stock at December 31, 2018 or 2017.
- (4) The Company did not own any preferred stock at December 31, 2018 or 2017.
- (5) The Company did not have any mortgage loans at December 31, 2018 or 2017.
- (6) Securities Lending

The Company engages in securities lending by lending certain securities from its investment portfolio to other institutions for short periods of time. Borrowers must post cash collateral in the amount of 102% to 105% of the fair value of a loaned security. The fair value of the loaned securities is monitored on a daily basis, with additional collateral obtained or refunded as the fair value of the loaned securities fluctuates. The collateral is retained and invested by a lending agent according to

the Company's guidelines to generate additional investment income for the Company. Pursuant to SSAP No. 103R - Transfers and Servicing of Financial Assets and Extinguishments of Liabilities ("SSAP No. 103R"), collateral required under the Company's securities lending program is carried on the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus as both a receivable and payable. Also pursuant to SSAP No. 103, if the collateral received from a counterparty is less than 100 percent at the reporting date, the difference between the actual collateral and 100 percent is nonadmitted. Collateral value is measured and compared to the loaned securities in aggregate by counterparty.

The Company did not have any loaned securities at December 31, 2018 and 2017

- (7) The Company did not have any investments in subsidiaries, controlled or affiliated companies at December 31, 2018 or 2017.
- (8) The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2018 or 2017.
- (9) The Company did not have any derivatives at December 31, 2018 or 2017.
- (10) Aggregate Health Policy Reserves and Related Expenses

Premium deficiency reserves ("PDR") are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Where allowed, anticipated investment income is considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts. The Company had no PDR at December 31, 2018 and 2017.

Unearned premium reserves ("UEP") are recognized for premiums that are recorded by the Company that have not been earned as of the statement date. The UEP Balances of \$5,869 and \$123,383 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2018 and 2017.

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual medical loss ratios ("MLR") were not met in the prior year. The Company's results for full-year 2018 and 2017 included estimates of \$1,320,783 and \$1,238,316, respectively, of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities and Capital and Surplus.

For Individual Medicare Part D, the Company's annual contract with Centers for Medicare & Medicaid Services ("CMS") provides a risk-sharing arrangement to limit exposure to unexpected expenses. The risk-sharing arrangement provides a risk corridor whereby the amount the Company received in premiums from members and CMS based on its annual bid is compared to actual drug costs incurred during the contract year. Based on the risk corridor provision and Part D activity-to-date, estimated risk-sharing payables of \$21,102 and \$39,248 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2018 and 2017, respectively

The Company reports liabilities associated with contracts subject to redetermination as aggregate health policy reserves in accordance with SSAP No. 54R – *Individual and Group and Accident Health Contracts* ("SSAP No. 54R") and SSAP No. 107 - *Risk-Sharing Provisions of the Affordable Care Act* ("SSAP No. 107"). The Company reported Affordable Care Act ("ACA") Risk Adjustment Payables of \$359,329 and \$781,458 in aggregate health policy reserves at December 31, 2018 and 2017, respectively.

- (11) Hospital and Medical Costs and Claims Adjustment Expenses and Related Reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid and aggregate health claim reserves include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing payment patterns, medical cost trends, historical utilization of health care services, claim inventory levels, medical inflation, contract requirement changes in membership and product mix, seasonality and

other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses in the period they are determined. Capitation costs, which are recorded in hospital and medical expenses in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

- (12) As a result of CVS Health's acquisition of Aetna Inc. ("Aetna"), Aetna modified its capitalization policy from the prior period related to furniture and equipment ("F&E") and prepaid assets. Under the revised policy, F&E will be capitalized if greater than \$1,000 versus the previous threshold of \$500. Under the new policy, prepaid assets will be capitalized if greater than \$250,000 versus the previous threshold of \$50,000. These revisions are not expected to have a material impact on the financial results of Aetna or its affiliates, including the Company.

(13) Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within forty five days of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables not in accordance with SSAP No. 84 – *Health Care and Government Insured Plan Receivables* or are over 90 days past due are nonadmitted. All rebates are processed and settled with an affiliated entity. The pharmaceutical rebate receivables are more fully discussed in Note 28.

(14) Premiums and Amounts Due and Unpaid

Premium revenue for prepaid health or dental care products is recognized as income in the month in which enrollees are entitled to health or dental care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums in the Statutory Statements of Liabilities, Capital and Surplus (refer to discussion of aggregate health policy reserves and related expenses above).

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

(15) Aggregate Health Claim Reserves

The reserve for future contingent benefits includes the estimated cost of services that will continue to be incurred after the Statutory Statements of Liabilities, Capital and Surplus date if the Company is obligated to pay for such services in accordance with contract provisions or regulatory requirements. These balances are recorded in aggregate health claim reserves in the Statutory Statements of Liabilities, Capital and Surplus and are estimated using a percentage of current hospital and medical costs, which is based on the Company's historical cost experience.

(16) Investment Income Due and Accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2018 and 2017, the Company did not have any nonadmitted investment income due and accrued.

(17) Covered and Uncovered Expenses and Related Liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

(18) Fees Paid to the Federal Government by Health Insurers

SSAP No. 106 - *Affordable Care Act Section 9010 Assessment* ("SSAP No. 106") required (1) that the health insurer fee be recognized in full on January 1 of the fee year (the calendar year in which the assessment must be paid to the federal government), in the operating expense category of insurance taxes, licenses and fees, excluding federal income taxes and (2) that in each data year preceding a fee year a reporting entity pro-ratably accrue by reclassifying from unassigned funds (surplus) to aggregate write-ins for special surplus funds an amount equal to its estimated subsequent fee year assessment. This reclassification has no impact on total capital and surplus and is reversed in full on January 1 of the fee year. On January 22, 2018, Public Law No: 115-120 was signed into law and it imposes a moratorium on the health insurer fee for calendar year 2019. As interpreted in INT 18-02: ACA Section 9010 Assessment Moratoriums, because there is not an ACA Section 9010 fee due in September 2019, there is not an accrual of a liability on January 1, 2019 based on 2018 data year net written premiums. Accrual of a liability on January 1, 2020 for the ACA Section 9010 assessment based on 2019 data year net written premiums and the reclassification from unassigned funds (surplus) to aggregate write-ins for special surplus funds equal to the estimated 2020 fee year assessment accrued in data year 2019 will both continue as prescribed under SSAP No. 106. See Note 22 for disclosure of all amounts related to the health insurer fee for the Company.

(19) The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's (collectively, "Health Care Reform") Risk Adjustment

Risk Adjustment

Health Care Reform established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company's qualified plan members relative to the average risk of members of other qualified plans in comparable markets, the Company estimates its ultimate risk adjustment receivable or payable for the current calendar year and reflects the impact as an adjustment to its premium revenue in accordance with SSAP No. 107.

(20) Federal and State Income and Premium Taxes

The Company was included in the consolidated federal income tax return of its parent company, Aetna and Aetna's other wholly-owned subsidiaries through November 27, 2018 pursuant to the terms of a tax sharing agreement. For the tax period ending December 31, 2018, Aetna and its wholly-owned subsidiaries are included in the consolidated federal income tax return of its parent, CVS Health, pursuant to the terms of a tax sharing agreement (and a Supplemental Tax Sharing Agreement where applicable) between CVS Health and the Company. In accordance with both agreements, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent realized in the consolidated return. Pursuant to these agreements, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary

differences generated by statutory accounting as defined in SSAP No. 101 - Income Taxes. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

a. Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Service ("IRS") tax loss carryback provisions.

b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

The Company is subject to state income taxes in various states. State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. For the years ended December 31, 2018 and 2017, the Company incurred state income tax expenses of \$123,104 and \$344,485, respectively. The Company's state income tax receivables of \$573,548 and \$233,184 at December 31, 2018 and 2017, respectively, were included as an aggregate write-in in the Statutory Statement of Assets.

(21) Reinsurance

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. The reinsurance coverage does not relieve the Company of its primary obligations. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums ceded for medical losses and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreements are more fully discussed in Notes 10 and 23.

D. Going Concern

As of March 1, 2019, management evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern and

management has determined that it is not probable that the Company will be unable to meet its obligations as they become due within one year after the financial statements are available to be issued. Management will continuously evaluate the Company's ability to continue as a going concern and will take appropriate action and will make appropriate disclosures if there is any change in any condition or events that would raise substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

The Company did not have any accounting changes or correction of errors in the years ended December 31, 2018 and 2017.

3. Business Combinations and Goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2018 and 2017.

4. Discontinued Operations

The Company did not have any discontinued operations in the years ending December 31, 2018 and 2017.

5. Investments

A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2018 or 2017.

B. The Company did not have any debt restructuring in the years ending December 31, 2018 and 2017.

C. The Company did not have any reverse mortgages at December 31, 2018 or 2017.

D. Loan-Backed Securities

- (1) Prepayment assumptions for single class and multi-class mortgage-backed/loan-backed securities were obtained from industry market sources.
- (2) The Company did not recognize any other-than-temporary impairments ("OTTI") on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R - *Loan-Backed and Structured Securities* ("SSAP No. 43R") at 2018 on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R - *Loan-Backed and Structured Securities* ("SSAP No. 43R").
- (3) The Company had no recognized OTTI on loan-backed and structured securities currently held, in which the present value of cash flows expected to be collected is less than the amortized cost basis at December 31, 2018.
- (4) The Company had no unrealized loss position on loan-backed and structured securities held by the Company at December 31, 2018.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not have any repurchase agreements or loaned securities transactions at December 31, 2018.
- (2) The Company did not pledge any of its assets as collateral, which are classified as securities pledged to creditors as of December 31, 2018.
- (3) Neither the Company nor its agent has accepted collateral that is permitted by contract or custom to sell or repledge as of December 31, 2018.
- (4) The Company did not have securities lending transactions administered by an affiliated agent which is "one line" reported at December 31, 2018.

- (5) The Company did not have any repurchase agreements, loaned securities or dollar repurchase agreements at December 31, 2018.
- (6) The Company has not accepted collateral that is not permitted by contract or custom to sell or repledge as of December 31, 2018.
- (7) The Company did not have any collateral for transactions that extend beyond one year from the reporting date.
- F. The Company did not have any repurchase agreements transactions accounted for as secured borrowing at December 31, 2018 or 2017.
- G. The Company did not have any reverse repurchase agreements transactions accounted for as secured atDecember 31, 2018 or 2017.
- H. The Company did not have any repurchase agreements transactions accounted for as a sale at December 31, 2018 or 2017.
- I. The Company did not have any reverse repurchase agreements transactions accounted for as a sale at December 31, 2018 or 2017.
- J. The Company did not have any real estate at December 31, 2018 or 2017.
- K. The Company did not have any low-income housing tax credits at December 31, 2018.
- L. Restricted Assets

(1) Restricted assets (including pledged):

Restricted Asset Category	1 Total Gross (Admitted & Nonadmitted) Restricted from Current Year	2 Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	3 Increase/ (Decrease) (1 minus 2)	4 Total Current Year Nonadmitted Restricted	5 Total Current Year Admitted Restricted (1 minus 4)	6 Gross (Admitted & Nonadmitted) Restricted to Total Assets	7 Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown						—	—
b. Collateral held under security lending agreements						—	—
c. Subject to repurchase agreements						—	—
d. Subject to reverse repurchase agreements						—	—
e. Subject to dollar repurchase agreements						—	—
f. Subject to dollar reverse repurchase agreements						—	—
g. Placed under option contracts						—	—
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock						—	—
i. FHLB capital stock						—	—
j. On deposit with states	\$400,899	\$401,538	(\$639)		\$400,899	107.278%	107.641%
k. On deposit with other regulatory bodies						—	—
l. Pledged collateral to FHLB (including assets backing funding agreements)						—	—
m. Pledged as collateral not captured in other categories						—	—
n. Other restricted assets						—	—
o. Total Restricted Assets	\$400,899	\$401,538	(\$639)	\$—	\$400,899	107.278%	107.641%

(a) Column 1 divided by Asset Page, Column 1, Line 28
(b) Column 5 divided by Asset Page, Column 3, Line 28

- (2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2018.
- (3) The Company did not have any other restricted assets at December 31, 2018.
- (4) The Company did not have any collateral received and reflected within its financial statements at December 31, 2018.
- M. The Company did not have any working capital finance investments at December 31, 2018.
- N. The Company did not have any offsetting and netting of derivative, repurchase and reverse repurchase, and securities borrowing and securities lending assets or liabilities at December 31, 2018.

- O. The Company did not have any structured notes at December 31, 2018.
- P. The Company did not have any 5GI* securities at December 31, 2018.
- Q. The Company did not have any short sales within the reporting period. December 31, 2018.
- R. The Company did not have any prepayment penalty and acceleration fees at December 31, 2018.

6. Joint Ventures, Partnerships, and Limited Liability Companies

- A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2018 or 2017.
- B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2018 or 2017.

7. Investment Income

- A. Due and accrued income was excluded from surplus on the following bases:

- Bonds - where collection of interest is uncertain.
- Preferred stock - where collection of dividends is uncertain.
- Mortgage loans - all due and accrued interest on loans delinquent for more than one year and on other loans where collection of interest is uncertain.
- Real estate - where rent is in arrears for more than three months.
- Contract loans - where accrued interest is in excess of loan value.

- B. There was no amount excluded at December 31, 2018 or 2017.

8. Derivative Instruments

The Company did not have any derivative instruments at December 31, 2018 or 2017.

9. Income Taxes

- A.
 - (1) The components of the net DTAs recognized in the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus are as follows:

	As of End of Current Period			12/31/2017			Change		
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
(a) Gross Deferred Tax Assets	\$47,535	\$78,625	\$126,160	\$20,863	\$173,633	\$194,496	\$26,672	(\$95,008)	(\$68,336)
(b) Statutory Valuation Allowance Adjustment	—	77,740	77,740			—	—	77,740	77,740
(c) Adjusted Gross Deferred Tax Assets (1a - 1b)	47,535	885	48,420	20,863	173,633	194,496	26,672	(172,748)	(146,076)
(d) Deferred Tax Assets Nonadmitted			—			—	—	—	—
(e) Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	47,535	885	48,420	20,863	173,633	194,496	26,672	(172,748)	(146,076)
(f) Deferred Tax Liabilities	73,467	—	73,467	7,196	94,719	101,915	66,271	(94,719)	(28,448)
(g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	(\$25,932)	\$885	(\$25,047)	\$13,667	\$78,914	\$92,581	(\$39,599)	(\$78,029)	(\$117,628)

- (2) The amount of admitted gross DTAs admitted under each component of SSAP No. 101:

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

	As of End of Current Period			12/31/2017			Change		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	(Col. 1 + 2) Total	Ordinary	Capital	(Col. 4 + 5) Total	(Col. 1 - 4) Ordinary	(Col. 2 - 5) Capital	(Col. 7 + 8) Total
Admission Calculation Components SSAP No. 101									
(a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks.	\$47,354	\$885	\$48,239	\$20,741	\$20,921	\$41,662	\$26,613	(\$20,036)	\$6,577
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2	181	0	181	123	67,828	67,951	58	(67,828)	(67,770)
1. Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date.	181	0	181	123	67,828	67,951	58	(67,828)	(67,770)
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.			3,386,381			2,618,186			768,195
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities	0	0	0		84,884	84,884	0	(84,884)	(84,884)
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$47,535	\$885	\$48,420	\$20,864	\$173,633	\$194,497	\$26,671	(\$172,748)	(\$146,077)

3.

	2018	2017
a. Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.	913%	606%
b. Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.	\$22,575,874	\$17,454,575

(4) The impact of tax planning strategies is as follows:

	As of End of Current Period		12/31/2017		Change	
	(1)	(2)	(3)	(4)	(5)	(6)
	Ordinary	Capital	Ordinary	Capital	(Col. 1 - 3) Ordinary	(Col. 2 - 4) Capital
Impact of Tax Planning Strategies:						
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.						
1. Adjusted Gross DTAs amount from Note 9A1(c)	\$47,535	\$885	\$20,863	\$173,633	\$26,672	(\$172,748)
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0%	0%	0%	35%	0%	(35)%
3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	\$47,535	\$885	\$20,863	\$173,633	\$26,672	(\$172,748)
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	0%	0%	0%	35%	0%	(35)%

b Do the Company's tax-planning strategies include the use of reinsurance? Yes [] No [X]

B. There are no DTLs that were not recognized at December 31, 2018 or 2017.

C. Current income taxes incurred consist of the following major components:

	(1) As of End of Current Period	(2) 12/31/2017	(3) (Col. 1 - 2) Change
1. Current Income Tax			
(a) Federal	\$1,683,679	\$1,800,566	(\$116,887)
(b) Foreign			—
(c) Subtotal	1,683,679	1,800,566	(116,887)
(d) Federal income tax on net capital gains	(55,750)	885	(56,635)
(e) Utilization of capital loss carry-forwards			—
(f) Other			—
(g) Federal and foreign income taxes incurred	\$1,627,929	\$1,801,451	(\$173,522)
2. Deferred Tax Assets:			
(a) Ordinary:			
(1) Discounting of unpaid losses	\$18,062	\$12,212	\$5,850
(2) Unearned premium reserve	756	1,173	(417)
(10) Receivables - nonadmitted	26,474	5,189	21,285
(13) Other (including items <5% of total ordinary tax assets)	2,243	2,289	(46)
(99) Subtotal	47,535	20,863	26,672
(b) Statutory valuation allowance adjustment			—
(c) Nonadmitted			—
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	47,535	20,863	26,672
(e) Capital:			
(1) Investments	78,625	173,633	(95,008)
(99) Subtotal	78,625	173,633	(95,008)
(f) Statutory valuation allowance adjustment	77,740		77,740
(g) Nonadmitted			0
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	885	173,633	(172,748)
(i) Admitted deferred tax assets (2d + 2h)	48,420	194,496	(146,076)
3. Deferred Tax Liabilities:			
(a) Ordinary:			
(1) Investments	61,333		61,333
(5) Other (including items <5% of total ordinary tax liabilities)	12,134	7,196	4,938
(99) Subtotal	73,467	7,196	66,271
(b) Capital:			
(1) Investments		94,719	(94,719)
(99) Subtotal	0	94,719	(94,719)
(c) Deferred tax liabilities (3a99 + 3b99)	73,467	101,915	(28,448)
4. Net deferred tax assets/liabilities (2i - 3c)	(\$25,047)	\$92,581	(\$117,628)

The change in net deferred income taxes is comprised of the following:

	12/31/2018	12/31/2017	Change
Total Deferred Tax Assets	\$48,420	\$194,496	(\$146,076)
Total Deferred Tax Liabilities	(73,467)	(101,915)	28,448
Net Deferred Tax Assets/(Liabilities)	(\$25,047)	\$92,581	(\$117,628)
Tax Effect of Unrealized Gains/(Losses)			0
Change in Net Deferred Income Tax			(\$117,628)

The valuation allowance adjustment to gross DTAs was \$77,740 and \$0 for December 31, 2018 and 2017, respectively.

D. The provision for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

	12/31/2018	Effective Tax Rate	12/31/2017	Effective Tax Rate
Provision computed at statutory rate	\$1,443,882	21.0%	\$2,236,603	35.0%
Health Insurer Fee	328,343	4.8%		0.0%
Transfer Pricing Adjustment	(184,504)	-2.7%	(436,067)	-6.8%
Tax-Exempt Interest	—	0.0%		0.0%
Change in Nonadmitted Assets	(21,285)	-0.3%	(4,834)	-0.1%
Prior Year True-Up	101,380	1.5%	59,651	0.9%
Change in Valuation Allowance Adjustment	77,740	1.1%		0.0%
Impact on Deferred Tax for Enacted Rate Change	—	0.0%	61,721	1.0%
Other	1	0.0%		0.0%
Total	\$1,745,557	25.4%	\$1,917,074	30.0%
Federal and foreign income taxes incurred	\$1,627,929	23.7%	\$1,801,451	28.2%
Change in net deferred income taxes	117,628	1.7%	115,623	1.8%
Total statutory income taxes	\$1,745,557	25.4%	\$1,917,074	30.0%

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm’s length prices as compared to what would be charged to an unrelated entity, which results in a permanent deduction for tax reporting purposes.

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “TCJA”) was enacted, which among other items, reduces the federal corporate tax rate to 21% effective January 1, 2018. The Company re-measured its deferred income taxes for the year-ended December 31, 2017 and recognized incremental tax expense (benefit) related to the change in its net deferred tax asset/liability. The accounting for income tax effects of the TCJA related to life insurance reserves were provisional at December 31, 2017. Accordingly, the items were recorded at a reasonable estimate at December 31, 2017.

E.

- (1) At December 31, 2018 and 2017, the Company had no net capital loss or net operating loss carryforwards for tax purposes.
- (2) The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is as follows:

Year	Ordinary	Capital	Total
2018	\$131,857	\$0	\$131,857
2018	1,450,430	0	1,450,430
2017	N/A	885	885
Total	\$1,582,287	\$885	\$1,583,172

- (3) The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2018 and 2017.

F.

- (1) At December 31, 2018, the Company's Federal Income Tax Return was consolidated with the following entities:

Aetna Inc.	CVS Health Corporation
@ Credentials Inc.	Accendo Insurance Company
Accordant Common, LLC	Accordant Health Services, LLC
Accuscript MO, Inc.	ACS Acqco Corp.
Active Health Management, Inc.	Adminco, Inc.
Administrative Enterprises, Inc.	Advanced Care Scripts, Inc.
Advanced Healthcare Distributors, LLC	AdvancePCS Specialty Rx, LLC
ADVANCERX.COM, LLC	Aetna Asset Advisors, LLC
Aetna Behavioral Health, LLC	Aetna Better Health Inc. (Georgia)
Aetna Better Health Inc. (IL)	Aetna Better Health Inc. (NJ)
Aetna Better Health Inc. (NY)	Aetna Better Health Inc. (OH)

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

Aetna Better Health Inc. (Tennessee)	Aetna Better Health of California, Inc.
Aetna Better Health of Iowa, Inc.	Aetna Better Health of Kansas Inc.
Aetna Better Health of Kentucky Insurance Co.	Aetna Better Health of Michigan, Inc.
Aetna Better Health of Missouri LLC	Aetna Better Health of Nevada Inc.
Aetna Better Health of North Carolina, Inc.	Aetna Better Health of Oklahoma Inc.
Aetna Better Health of Texas, Inc.	Aetna Better Health of Washington, Inc.
Aetna Better Health, Inc. (Connecticut)	Aetna Better Health, Inc. (LA)
Aetna Better Health, Inc. (PA)	Aetna Capital Management, LLC
Aetna Card Solutions, LLC	Aetna Dental Inc. (New Jersey)
Aetna Dental Inc. (Texas)	Aetna Dental of California, Inc.
Aetna Financial Holdings, LLC	Aetna Florida, Inc.
Aetna Health Holdings, LLC	Aetna Health Inc. (Connecticut)
Aetna Health Inc. (Florida)	Aetna Health Inc. (Georgia)
Aetna Health Inc. (LA)	Aetna Health Inc. (Maine)
Aetna Health Inc. (Michigan)	Aetna Health Inc. (New Jersey)
Aetna Health Inc. (NY)	Aetna Health Inc. (Pennsylvania)
Aetna Health Inc. (Texas)	Aetna Health Insurance Company
Aetna Health Insurance Company of New York	Aetna Health Management, LLC
Aetna Health of California Inc.	Aetna Health of Iowa, Inc
Aetna Health of Utah, Inc.	Aetna HealthAssurance Pennsylvania, Inc.
Aetna Integrated Informatics, Inc.	Aetna International Inc.
Aetna Ireland Inc.	Aetna Life & Casualty (Bermuda) Limited
Aetna Medicaid Administrators LLC	Aetna Network Services LLC
Aetna Pharmacy Management Services, LLC	Aetna Risk Assurance Company of Connecticut
Aetna Rx Home Delivery, LLC	Aetna Specialty Pharmacy, LLC
Aetna Student Health Agency, Inc.	Aetna Workers' Comp Access, LLC
Alabama CVS Pharmacy, LLC	Alajasper Realty Services, LLC
Alaska CVS Pharmacy, LLC	Allviant Corporation
AMC - New York, Inc.	AMC - Tennessee, Inc.
American Drug Stores Delaware, LLC	American Health Holding, Inc.
Apria Finance Holdings, Inc.	APS Acquisition LLC
APS-Summit Care Pharmacy, LLC	Arizona CVS Stores, LLC
Arkansas CVS Pharmacy, LLC	ASCO Healthcare of New England Limited Partnership
ASCO HealthCare, LLC	ASI Wings, LLC
AUSHC Holdings, Inc. (CT)	Badger Acquisition LLC
Badger Acquisition of Kentucky, LLC	Badger Acquisition of Minnesota, LLC
Badger Acquisition of Ohio, LLC	Baumel Eisner Neuromedical Institute, LLC
Best Care LTC Acquisition Company, LLC	Bluegrass Pharmacy of Lexington, LLC
BPNY Acquisition Corp	Bruin Acquisition Co., Inc.
bswift, LLC	Busse CVS, LLC #3110
Campo's Medical Pharmacy, Inc.	Care Pharmaceutical Services, LP
Care4, LP	Carecenter Pharmacy, LLC
Carecenter Pharmacy, LLC	Carefree Insurance Services, Inc.
Caremark Arizona Specialty Pharmacy Holding, LLC	Caremark Arizona Specialty Pharmacy, LLC
Caremark California Specialty Pharmacy Holding, LLC	Caremark California Specialty Pharmacy, LLC
Caremark Dallas Pharmacy, LLC	Caremark Hawaii Mail Pharmacy Holding, LLC
Caremark Hawaii Mail Pharmacy, LLC	Caremark Illinois Mail Pharmacy Holding, LLC
Caremark Irving Resource Center Holding, LLC	Caremark Irving Resource Center, LLC
Caremark Ohio Specialty Pharmacy Holding, LLC	Caremark Ohio Specialty Pharmacy, LLC
Caremark PA Specialty Pharmacy Holding, LLC	Caremark PCS, LLC
Caremark Pennsylvania Specialty Pharmacy, LLC	Caremark PHC, LLC
Caremark Puerto Rico Holding, LLC	Caremark Puerto Rico Specialty Pharmacy Holding, LLC
Caremark Puerto Rico Specialty Pharmacy, LLC	Caremark Puerto Rico, LLC
Caremark Redlands Pharmacy, LLC	Caremark Rx, LLC
Caremark Texas Mail Pharmacy Holding, LLC	Caremark Texas Mail Pharmacy, LLC
Caremark Ulysses Holding Corp.	Caremark, LLC
CaremarkPCS Alabama Mail Pharmacy Holding, LLC	CaremarkPCS Alabama Mail Pharmacy, LLC
CaremarkPCS Health, LLC	CaremarkPCS Pennsylvania Mail Pharmacy Holding, LLC
CaremarkPCS Pennsylvania Mail Pharmacy, LLC	CC Advertising & Marketing, LLC
CCRx Holdings, LLC	CCRx of North Carolina Holdings, LLC
CCRx of North Carolina, LLC	Central Rx Services, LLC
Choice Source Therapeutic Of Houston, Texas, LLC	Choice Source, LLC
CHP Acquisition Corp.	Circle Tallahassee Re, LLC

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

Claims Administration Corporation	Cofinity, Inc.
Compass Health Services, LLC	CompScript, LLC
Connecticut CVS Pharmacy, LLC	Continuing Care RX, LLC
Coram Alternate Site Services, Inc.	Coram Clinical Trials, Inc.
Coram Healthcare Corporation of Alabama	Coram Healthcare Corporation Of Florida
Coram Healthcare Corporation Of Greater D.C.	Coram Healthcare Corporation of Greater New York
Coram Healthcare Corporation of Indiana	Coram Healthcare Corporation of Massachusetts
Coram Healthcare Corporation of Mississippi	Coram Healthcare Corporation of Nevada
Coram Healthcare Corporation of North Texas	Coram Healthcare Corporation of Northern California
Coram Healthcare Corporation of Southern California	Coram Healthcare Corporation Of Southern Florida
Coram Healthcare Corporation of Utah	Coram LLC
Coram Specialty Infusion Services, LLC	CoramRX, LLC
Corporate Benefit Strategies, Inc.	Coventry Consumer Advantage, Inc.
Coventry Health and Life Insurance Company	Coventry Health Care National Accounts, Inc.
Coventry Health Care National Network, Inc.	Coventry Health Care of Florida, Inc.
Coventry Health Care of Illinois, Inc.	Coventry Health Care of Kansas, Inc.
Coventry Health Care of Missouri, Inc.	Coventry Health Care of Nebraska, Inc.
Coventry Health Care of Virginia, Inc.	Coventry Health Care of West Virginia, Inc.
Coventry Health Care Workers Compensation, Inc.	Coventry Health Plan of Florida, Inc.
Coventry HealthCare Management Corporation	Coventry Prescription Management Services, Inc.
Coventry Rehabilitation Services, Inc.	Coventry Transplant Network, Inc.
CP Acquisition Corp.	CP Services LLC
CSR, Inc.	CVS 1001 MA, LLC
CVS 10015 MA, LLC	CVS 10019 AR, LLC
CVS 10024 VA, LLC	CVS 10049 KY, LLC
CVS 10078 FL, LLC	CVS 10099 DE, LLC
CVS 10117 VA, LLC	CVS 10125 MA, LLC
CVS 10154 GA, LLC	CVS 10170 VA, LLC
CVS 10175 OK, LLC	CVS 10196 MA, LLC
CVS 10201 MN, LLC	CVS 10206 AL, LLC
CVS 10208 AL, LLC	CVS 10238 DE, LLC
CVS 10242 NE, LLC	CVS 10251 VA, LLC
CVS 10273 OK, LLC	CVS 10275 OK, LLC
CVS 10279 KY, LLC	CVS 10286 VA, LLC
CVS 10320 VA, LLC	CVS 10326 OK, LLC
CVS 10346 FL, LLC	CVS 10374 OH, LLC
CVS 10376 DE, LLC	CVS 10396 MN, LLC
CVS 1041 MA, LLC	CVS 10410 NE, LLC
CVS 10419 WI, LLC	CVS 10422 VA, LLC
CVS 10430 AR, LLC	CVS 10432 AR, LLC
CVS 10453 VA, LLC	CVS 10454 VA, LLC
CVS 10501 MA, LLC	CVS 10504 FL, LLC
CVS 10515 TN, LLC	CVS 10518 AR, LLC
CVS 10533 WI, LLC	CVS 10534 AR, LLC
CVS 10539 AR, LLC	CVS 10560 OK, LLC
CVS 10563 VA, LLC	CVS 10586 VA, LLC
CVS 10589 GA, LLC	CVS 10644 FL, LLC
CVS 10666 AR, LLC	CVS 10683 KY, LLC
CVS 10684 VA, LLC	CVS 10746 VA, LLC
CVS 10756 MN, LLC	CVS 10768 VA, LLC
CVS 10770 VA, LLC	CVS 10779 AR, LLC
CVS 10781 CO, LLC	CVS 10782 CO, LLC
CVS 10783 CO, LLC	CVS 10784 CO, LLC
CVS 10785 CO, LLC	CVS 10787 SC, LLC
CVS 10788 KY, LLC	CVS 1079 GA, LLC
CVS 10811 AL, LLC	CVS 10812 KY, LLC
CVS 10816 AR, LLC	CVS 10830 CO, LLC
CVS 10831 CO, LLC	CVS 10836 MA, LLC
CVS 10893 OH, LLC	CVS 10898 AL, LLC
CVS 10937 VA, LLC	CVS 10949 TN, LLC
CVS 10958 CO, LLC	CVS 10967 VA, LLC
CVS 10968 VA, LLC	CVS 10975 AR, LLC
CVS 10976 OK, LLC	CVS 10990 VA, LLC

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

CVS 10992 VA, LLC	CVS 11000 CO, LLC
CVS 11001 CO, LLC	CVS 11002 CO, LLC
CVS 11016 AL, LLC	CVS 11017 GA, LLC
CVS 11019 KY, LLC	CVS 11024 CO, LLC
CVS 11056 VA, LLC	CVS 11070 MN, LLC
CVS 11083 VA, LLC	CVS 11086 OH, LLC
CVS 11089 KY, LLC	CVS 11092 OK, LLC
CVS 11093 AR, LLC	CVS 11104 CO, LLC
CVS 11105 CO, LLC	CVS 11115 VA, LLC
CVS 11155 OH, LLC	CVS 11158 AR, LLC
CVS 11179 VA, LLC	CVS 11233 VA, LLC
CVS 1126 FL, LLC	CVS 1131 MA, LLC
CVS 11337 CO, LLC	CVS 1194 SC, LLC
CVS 1200 SC, LLC	CVS 1383 VA, LLC
CVS 1420 GA, LLC	CVS 1427, LLC
CVS 1435 MD, LLC	CVS 1452 MD, LLC
CVS 1461 MD, LLC	CVS 1525 VA, LLC
CVS 1538 VA, LLC	CVS 1547 VA, LLC
CVS 1556 VA, LLC	CVS 1561 VA, LLC
CVS 1589 MI, LLC	CVS 1743 AZ, LLC
CVS 180 SC, LLC	CVS 1803 MA, LLC
CVS 2003 VA, LLC	CVS 2004 VA, LLC
CVS 2019 VA, LLC	CVS 2048 RI, LLC
CVS 2065 RI, LLC	CVS 2212 GA, LLC
CVS 2545 CT, LLC	CVS 264 NJ, LLC
CVS 2747 FL, LLC	CVS 2776 VA, LLC
CVS 2829 FL, LLC	CVS 2948 Henderson, LLC #2948
CVS 301 MA, LLC	CVS 3042 DE, LLC
CVS 3121 FL, LLC	CVS 3186 WV, LLC
CVS 3227 FL, LLC	CVS 3232 NC, LLC
CVS 3250 FL, LLC	CVS 3257 FL, LLC
CVS 326 RI, LLC	CVS 3268 Gilbert, LLC #3268
CVS 3269 FL, LLC	CVS 3271 FL, LLC
CVS 3301 OH, LLC	CVS 3318 FL, LLC
CVS 3320 OH, LLC	CVS 3343 OH, LLC
CVS 3353 OH, LLC	CVS 3356 OH, LLC
CVS 3380 SC, LLC	CVS 3407 OH, LLC
CVS 3416 OH, LLC	CVS 3418 FL, LLC
CVS 3432 OH, LLC	CVS 3452 OH, LLC
CVS 3460 VA, LLC	CVS 3468 OH, LLC
CVS 3471 OH, LLC	CVS 3537 SC, LLC
CVS 3558 NV, LLC	CVS 3563 NC, LLC
CVS 3625 AZ, LLC	CVS 3667 FL, LLC
CVS 373 MA, LLC	CVS 3745 Peoria, LLC #3745
CVS 3749 AZ, LLC	CVS 3805 SC, LLC
CVS 3818 FL, LLC	CVS 3831 NC, LLC
CVS 3833 NC, LLC	CVS 3923 FL, LLC
CVS 3965 AZ, LLC	CVS 3967 AZ, LLC
CVS 397 RI, LLC	CVS 3973 NC, LLC
CVS 3987 NC, LLC	CVS 3988 NC, LLC
CVS 4015 FL, LLC	CVS 4016 MA, LLC
CVS 4073 MA, LLC	CVS 410 FL, LLC
CVS 4110 TN, LLC	CVS 4153 SC, LLC
CVS 4225 MD, LLC	CVS 4300 OH, LLC
CVS 433 MA, LLC	CVS 4331 OH, LLC
CVS 4380 WI, LLC	CVS 4419 WV, LLC
CVS 4480 FL, LLC	CVS 4485 FL, LLC
CVS 449 MA, LLC	CVS 4519 MS, LLC
CVS 4523 SC, LLC	CVS 4533 TN, LLC
CVS 4536 MS, LLC	CVS 4544 RI, LLC (f/k/a CVS 75566 RI, LLC)
CVS 4639 FL, LLC	CVS 4669 GA, LLC
CVS 4672 GA, LLC	CVS 4695 GA, LLC
CVS 4738 FL, LLC (f/k/a CVS 75462 FL, LLC)	CVS 4769 SC, LLC

CVS 4795 AZ, LLC	CVS 4832 AL, LLC
CVS 4840 AL, LLC	CVS 4853 AL, LLC
CVS 4896 OK, LLC	CVS 4900 AL, LLC
CVS 4905 AL, LLC	CVS 4944 AL, LLC
CVS 4976 AL, LLC	CVS 4981 MA, LLC
CVS 4993 MS, LLC	CVS 5018 TN, LLC
CVS 5021 VA, LLC	CVS 5029 AZ, LLC
CVS 5089 NY, LLC	CVS 5111 FL, LLC
CVS 5112 FL, LLC	CVS 5113 NV, LLC
CVS 5131 AZ, LLC	CVS 516 VA, LLC
CVS 5165 FL, LLC	CVS 5168 MS, LLC
CVS 5180 FL, LLC	CVS 5271 KS, LLC
CVS 5282 LA, LLC	CVS 5354 LA, LLC
CVS 5374 LA, LLC	CVS 5375 FL, LLC
CVS 5382 IL, LLC	CVS 5419 SC, LLC
CVS 5432 LA, LLC	CVS 5448 FL, LLC
CVS 5467 VA, LLC	CVS 5469 LA, LLC
CVS 5492 MN, LLC	CVS 5523 GA, LLC
CVS 5537 NC, LLC	CVS 5542 SC, LLC
CVS 5545 NC, LLC	CVS 5552 SC, LLC
CVS 5568 NC, LLC	CVS 5577 NC, LLC
CVS 5585 NC, LLC	CVS 5589 FL, LLC
CVS 5595 NC, LLC	CVS 5616 MN, LLC
CVS 5622 GA, LLC	CVS 5625 MO, LLC
CVS 5680 GA, LLC	CVS 5683 GA, LLC
CVS 5740 MS, LLC	CVS 5779 AZ, LLC
CVS 5783 IL, LLC	CVS 5791 AZ, LLC
CVS 5793 AZ, LLC	CVS 5801 MS, LLC
CVS 5812 AZ, LLC	CVS 5815 FL, LLC
CVS 5816 FL, LLC	CVS 582 MA, LLC
CVS 5828 CA, LLC	CVS 5829 IL, LLC
CVS 5849 AZ, LLC	CVS 5850 MS, LLC
CVS 5851 IL, LLC	CVS 5856 MA, LLC
CVS 5890 AZ, LLC	CVS 5891 AZ, LLC
CVS 5892 AZ, LLC	CVS 5893 AZ, LLC
CVS 590 RI, LLC	CVS 5931 AZ, LLC
CVS 5934 AZ, LLC	CVS 6009 OK, LLC
CVS 6012 GA, LLC	CVS 6073 NJ, LLC
CVS 6089 OH, LLC	CVS 6116 KY, LLC
CVS 612 MA, LLC	CVS 6135 NJ, LLC
CVS 6142 OK, LLC	CVS 6201 MN, LLC
CVS 6233 OK, LLC	CVS 6304 TN, LLC
CVS 6305 WV, LLC	CVS 6306 WV, LLC
CVS 6342 KY, LLC	CVS 6349 OH, LLC
CVS 6363 TN, LLC	CVS 6384 KY, LLC
CVS 6395 TN, LLC	CVS 6413 TN, LLC
CVS 6423, LLC	CVS 6429 TN, LLC
CVS 6572 IN. II, LLC	CVS 6572 IN., LLC
CVS 6796 MA, LLC	CVS 6852 VA, LLC
CVS 6867 NV, LLC	CVS 6869 DE, LLC
CVS 6874 IN, LLC	CVS 6941 KY, LLC
CVS 6972 FL, LLC	CVS 7036, LLC
CVS 7047, LLC	CVS 7057 NC, LLC
CVS 7070 MS, LLC	CVS 709 FL, LLC
CVS 7109 MA, LLC	CVS 7133 FL, LLC
CVS 7148 NC, LLC	CVS 7157 NC, LLC
CVS 7173 FL, LLC	CVS 7180 AL, LLC
CVS 7200, LLC	CVS 7215 AL, LLC
CVS 7382 NC, LLC	CVS 75024 AL, LLC
CVS 75121 SC, LLC	CVS 75124 MI, LLC
CVS 75129 FL, LLC	CVS 75137 MD, LLC
CVS 75139 NJ, LLC	CVS 75144 RI, LLC
CVS 75151 OH, LLC	CVS 75156 NV, LLC

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

CVS 75157 MI, LLC	CVS 75160 SC, LLC
CVS 75161 AZ, LLC	CVS 75162 AZ, LLC
CVS 75163 GA, LLC	CVS 75165 GA, LLC
CVS 7519 MN, LLC	CVS 75195 FL, LLC
CVS 75235 RI, LLC	CVS 75249 FL, LLC
CVS 75257 NJ, LLC	CVS 75269 MI, LLC
CVS 75275 TN, LLC	CVS 75280 NC, LLC
CVS 75294 FL, LLC	CVS 75307 KS, LLC
CVS 75312 VA, LLC	CVS 75334 FL, LLC
CVS 75363 GA, LLC	CVS 75365 GA, LLC
CVS 75374 NJ, LLC	CVS 75377 NC, LLC
CVS 75380 GA, LLC	CVS 75393 DE, LLC
CVS 75408 FL, LLC	CVS 75416 KY, LLC
CVS 75441 GA, LLC	CVS 75444 NV, LLC
CVS 75461 AL, LLC	CVS 75485 NC, LLC
CVS 75486 KS, LLC	CVS 75503 GA, LLC
CVS 75536 GA, LLC	CVS 75558 FL, LLC
CVS 75560 NJ, LLC	CVS 75561 NJ, LLC
CVS 75562 VA, LLC	CVS 75563 MD, LLC
CVS 75569 GA, LLC	CVS 75572 NC, LLC
CVS 75583 MA, LLC	CVS 75584 MA, LLC
CVS 75590 MN, LLC	CVS 75615 FL, LLC
CVS 75619 NJ, LLC	CVS 75626 GA, LLC
CVS 75636 NV, LLC	CVS 75642 VA, LLC
CVS 75651 SC, LLC	CVS 75659 OK, LLC
CVS 75660 OK, LLC	CVS 75669 MA, LLC
CVS 75676 KY, LLC	CVS 75679 SC, LLC
CVS 75707 FL, LLC	CVS 75718 OH, LLC
CVS 75719 MN, LLC	CVS 75733 NV, LLC
CVS 75738 RI, LLC	CVS 75740 NJ, LLC
CVS 75743 NJ, LLC	CVS 75770 NC, LLC
CVS 75771 NC, LLC	CVS 75774 MA, LLC
CVS 75795 DE, LLC	CVS 75799 NJ, LLC
CVS 75849 NC, LLC	CVS 75896 MA, LLC
CVS 75905 NJ, LLC	CVS 75924 FL, LLC
CVS 75935 NV, LLC	CVS 75946 VA, LLC
CVS 75947 GA, LLC	CVS 75952 WI, LLC
CVS 75958 MN, LLC	CVS 75959 MN, LLC
CVS 75961 SC, LLC	CVS 75977 MN, LLC
CVS 75978 FL, LLC	CVS 75995 DE, LLC
CVS 7648 KY, LLC	CVS 770 FL, LLC
CVS 7701, LLC	CVS 7885 GA, LLC
CVS 7888 GA, LLC	CVS 8003 MI, LLC
CVS 8009 MI, LLC	CVS 8067 MI, LLC
CVS 8071 MI, LLC	CVS 8078 MI, LLC
CVS 8086 MI, LLC	CVS 8103 MI, LLC
CVS 8123 MI, LLC	CVS 8133 MI, LLC
CVS 8165 MI, LLC	CVS 8207 MI, LLC
CVS 8281 MD, LLC	CVS 8302 MI, LLC
CVS 8303 TN, LLC	CVS 8415 NE, LLC
CVS 8549 MI, LLC	CVS 8615 NE, LLC
CVS 866 FL, LLC	CVS 8774 WI, LLC
CVS 8776 WI, LLC	CVS 8909 NC, LLC
CVS 8956 MS, LLC	CVS 8975 SC, LLC
CVS 8993 MS, LLC	CVS 920 MA, LLC
CVS 921 IL, LLC	CVS 932 FL, LLC
CVS 962 GA, LLC	CVS 9674 CA, LLC
CVS 976 FL, LLC	CVS AL Distribution, LLC
CVS ALBANY, LLC	CVS AOC Services, LLC
CVS ARCLIGHT, INC.	CVS Bay City 8207 MI, LLC
CVS Bellmore Avenue, LLC #2154	CVS Caremark Advanced Technology Pharmacy, LLC
CVS Caremark Indemnity Ltd.	CVS Caremark Part D Services, LLC
CVS Durham 7042, LLC	CVS EGL 5624 MO, LLC

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

CVS EGL 571 FL, LLC	CVS EGL 7958 FL, LLC
CVS ETB Holding Company, LLC	CVS Falmouth KY, LLC
CVS Foreign, Inc. #9736	CVS Gilbert 3272, LLC #3272
CVS Grand Bay 4782, LLC	CVS Greensboro, LLC
CVS Indiana, LLC #0877	CVS International, LLC
CVS Lagrange 4540, LLC	CVS Logan 3454, LLC
CVS Manchester NH, LLC #0200	CVS Michigan, LLC #9415
CVS Montgomery 6094, LLC	CVS NV Holding Company, LLC
CVS Orlando FL Distribution, LLC	CVS PA Distribution, LLC
CVS Pharmacy Inc.	CVS PR Center Inc.
CVS PR Center, Inc.	CVS PR Holding Company, LLC
CVS RCI, LLC	CVS RS Arizona, LLC
CVS Rx Services, Inc. #0886	CVS Safir Sourcing, LLC
CVS SC Distribution, LLC	CVS SP 5897 FL, LLC
CVS State Capital, LLC #0800	CVS TN Distribution, LLC
CVS Transportation, LLC	CVS TX Holding Company, LLC
CVS Vero FL Distribution, LLC	CVS Washington 6448, LLC
CVS Weymouth 1853, LLC	CVS WWRE, INC.
D&R Pharmaceutical Services, LLC	D.A.W., LLC
Delaware CVS Pharmacy, LLC	Delaware Physicians Care, Inc.
DG Danville KY, LLC	Digital EHealth, LLC
Digital Enterprise Realty, LLC	District Of Columbia CVS Pharmacy, LLC
E.T.B., INC.	Echo Merger Sub, Inc
Eckerd Corporation Of FL, Inc.	Employee Assistance Services, LLC
Enloe Drugs, LLC	Enterprise Safety Organization, LLC
Escalante Solutions, Llc	Evergreen Pharmaceutical of California, Inc.
Evergreen Pharmaceutical, LLC	Express Pharmacy Services of PA, LLC
First Health Group Corp.	First Health Life and Health Insurance Company
First Script Network Services, Inc.	Florida Health Plan Administrators, LLC
FOCUS Healthcare Management, Inc.	Garfield Beach CVS, LLC
Generation Health, LLC	Geneva Woods Health Services, LLC
Geneva Woods LTC Pharmacy, LLC	Geneva Woods Management, LLC
Geneva Woods Pharmacy Alaska, LLC	Geneva Woods Pharmacy Washington, LLC
Geneva Woods Pharmacy Wyoming, LLC	Geneva Woods Pharmacy, Inc.
Geneva Woods Retail Pharmacy, LLC	Georgia CVS Pharmacy, LLC
German Dobson CVS, LLC #5038	Goodyear CVS, LLC #3749
Grand St. Paul CVS, LLC	Grandview Pharmacy, LLC
Group Dental Service of Maryland, Inc.	Group Dental Service, Inc.
HCP Acquisition Sub, LLC	Health and Human Resource Center, Inc.
Health Data & Managment Solutions, Inc.	Health Re, Inc.
Healthagen LLC	HealthAssurance Pennsylvania, Inc.
Highland Park CVS, LLC	Holiday CVS, LLC
Home Care Pharmacy, LLC	Home Pharmacy Services, LLC
Hook-Superx, LLC	Horizon Behavioral Services, LLC
Idaho CVS Pharmacy, LLC	Institutional Health Care Services, LLC
Interlock Pharmacy Systems, LLC	Iowa CVS Pharmacy, LLC
Ironbound CVS Urban Renewal, LLC	iTriage, LLC
JEC Funding, Inc.	JHC Acquisition, LLC
Kansas CVS Pharmacy, LLC	Kentucky CVS Pharmacy, LLC
Langsam Health Services, LLC	LCPS Acquisition, LLC
LHS Acquisition Sub, LLC	Lobos Acquisition, LLC
Lo-Med Prescription Services, LLC	Longs Drug Stores California, LLC
Longs Drug Stores, LLC	Louisiana CVS Pharmacy, LLC
Managed Care Coordinators, Inc.	Managed Healthcare, Inc.
Martin Health Services, Inc.	Maryland CVS Pharmacy, LLC
Massachusetts CVS Pharmacy, Inc.	Med World Acquisition Corp.
Medical Arts Health Care, Inc.	Melville Realty Co., Inc.
Member Health, LLC	Mental Health Associates, Inc.
Mental Health Network of New York IPA, Inc.	Meritain Health, Inc.
Merwin IV & Specialty Pharmacy, LLC	Merwin Long Term Care, Inc.
Merwin Rx-Compounding Pharmacy, LLC	MetraComp, Inc.
MHHP Acquisition Company, LLC	MHNet Life and Health Insurance Company
MHNet of Florida, Inc.	MHNet Specialty Services LLC

Minuteclinic Diagnostic Of Alabama, LLC	Minuteclinic Diagnostic Of Arizona, LLC
Minuteclinic Diagnostic Of Florida, LLC	Minuteclinic Diagnostic Of Georgia, LLC
Minuteclinic Diagnostic Of Hawaii, LLC	Minuteclinic Diagnostic Of Illinois, LLC
Minuteclinic Diagnostic Of Kentucky, LLC	Minuteclinic Diagnostic Of Louisiana, LLC
Minuteclinic Diagnostic Of Maine, LLC	Minuteclinic Diagnostic Of Maryland, LLC
Minuteclinic Diagnostic Of Massachusetts, LLC	Minuteclinic Diagnostic Of Nebraska, LLC
Minuteclinic Diagnostic Of New Hampshire, LLC	Minuteclinic Diagnostic Of New Mexico, LLC
Minuteclinic Diagnostic Of Ohio, LLC	Minuteclinic Diagnostic Of Oklahoma, LLC
Minuteclinic Diagnostic Of Oregon, LLC	Minuteclinic Diagnostic Of Pennsylvania, LLC
Minuteclinic Diagnostic Of Rhode Island, LLC	Minuteclinic Diagnostic Of South Carolina, LLC
Minuteclinic Diagnostic Of Texas, LLC	Minuteclinic Diagnostic Of Utah, LLC
Minuteclinic Diagnostic Of Virginia, LLC	Minuteclinic Diagnostic Of Washington, LLC
Minuteclinic Diagnostic Of Wisconsin, LLC	Minuteclinic Online Diagnostic Services, LLC
Minuteclinic Telehealth Services, LLC	Minuteclinic, LLC
Mississippi CVS Pharmacy, LLC	Missouri CVS Pharmacy, LLC
Montana CVS Pharmacy, LLC	Mountain Grove Investment Group LLC
NCS Healthcare of Illinois, LLC	NCS Healthcare of Indiana LLC
NCS Healthcare of Iowa, LLC	NCS Healthcare of Kansas, LLC
NCS Healthcare of Kentucky, Inc.	NCS Healthcare of Montana, Inc.
NCS Healthcare of New Hampshire, Inc.	NCS Healthcare of New Mexico, Inc.
NCS Healthcare of Ohio, LLC	NCS Healthcare of South Carolina, Inc.
NCS Healthcare of Tennessee, Inc.	NCS Healthcare of Wisconsin, LLC
NCS Healthcare, LLC	NCSH Acquisition Sub, LLC
Nebraska CVS Pharmacy, LLC	NeighborCare Holdings, Inc.
NeighborCare of Indiana, LLC	NeighborCare of New Hampshire, LLC
NeighborCare of Virginia, LLC	NeighborCare Pharmacies, LLC
NeighborCare Pharmacy of Virginia, LLC	NeighborCare Pharmacy Services, Inc.
NeighborCare Services Corporation	NeighborCare, Inc.
Nevada CVS Pharmacy, LLC	New Jersey CVS Pharmacy, LLC
NH Acquisition Sub, LLC	Niagara Re, Inc.
NIV Acquisition, LLC	North Carolina CVS Pharmacy, LLC
North Shore Pharmacy Services LLC	Novologix, LLC
NS Acquisition Sub, LLC	NSPS Acquisition Sub, LLC
Ocean Acquisition Sub, LLC	OCR Services Corporation
OCR-RA Acquisition, LLC	Ohio CVS Stores, LLC
Oklahoma CVS Pharmacy, LLC	Omnicare Distribution Center LLC
Omnicare ESC LLC	Omnicare Foundation
Omnicare Headquarters LLC	Omnicare Holding Company
Omnicare Indiana Partnership Holding Company LLC	Omnicare of Nevada, LLC
Omnicare of New York, LLC	Omnicare Pharmacies of Pennsylvania East LLC
Omnicare Pharmacies of Pennsylvania West LLC	Omnicare Pharmacies of the Great Plains Holding Company
Omnicare Pharmacy and Supply Services LLC	Omnicare Pharmacy of Florida, LP
Omnicare Pharmacy of Maine LLC	Omnicare Pharmacy of Nebraska, LLC
Omnicare Pharmacy of North Carolina, LLC	Omnicare Pharmacy of Pueblo, LLC
Omnicare Pharmacy of Tennessee, LLC	Omnicare Pharmacy of Texas 1, LP
Omnicare Pharmacy of Texas 2, LP	Omnicare Pharmacy of the Midwest, LLC
Omnicare Property Management, LLC	Omnicare, Inc.
OPGP Acquisition Sub, LLC	OPM Acquisition Sub, LLC
Oregon CVS Pharmacy, LLC	Part D Holding Co., LLC
PayFlex Holdings, Inc.	PayFlex Systems USA, Inc.
Pennsylvania CVS Pharmacy, LLC	Pennsylvania Life Insurance Company
Performax, Inc.	Pharmacare Holding Company
Pharmacare Pharmacy, LLC	Pharmacare Specialty Healthcare Distributors, LLC
Pharmacy Associates of Glens Falls, Inc.	Pharmacy Consultants, LLC
Pharmacy Holding #1, LLC	Pharmacy Holding #2, LLC
PharmaSource Healthcare, Inc.	Pharm-Corp of Maine LLC
Pharmed Holdings, Inc.	Pharmore, Inc.
Phoenix Data Solutions LLC	PMRP Acquisition Company, LLC
PP Acquisition Company, LLC	Precision Benefit Services, Inc.
PrimeNet, Inc.	PRN Pharmaceutical Services, LP
Procure 4268 Yankee, LLC	Procure Pharmacy Direct, LLC
Procure Pharmacy, LLC	Prodigy Health Group, Inc.
Professional Pharmacy Services, Inc.	Professional Risk Management, Inc.

PSI Arkansas Acquisition, LLC	Puerto Rico CVS Pharmacy, LLC
Red Oak Sourcing, LLC	Resources for Living, LLC
Retrac, Inc. #107	Rhode Island CVS Pharmacy, LLC
Richmond Heights Acquisition Corp.	Roeschen's Healthcare LLC
Rx Innovations 4439, LLC	RxAMERICA, LLC
RXC Acquisition Company	Schaller Anderson Medical Administrators Inc
Scrip World, LLC	Sheffield Avenue CVS, LLC #3690
Shore Pharmaceutical Providers, LLC	Silverscript Insurance Company
Sky Acquisition LLC	South Carolina CVS Pharmacy, LLC
South Wabash CVS, LLC #3674	Specialized Pharmacy Services, LLC
Specialty Services Holding LLC	Speedwell CVS Urban Renewal, LLC
Sterling Healthcare Services, Inc.	Strategic Resource Company
Suburban Medical Services, LLC	Superior Care Pharmacy, Inc.
T2 Medical, Inc.	TCPI Acquisition Corp.
Tennessee CVs Pharmacy, LLC	The Vasquez Group, Inc.
Thomas Phoenix CVS, LLC #3625	Three Forks Apothecary, LLC
Thundermist Services, LLC	U.S. Health Care Properties, Inc.
UAC Holding, Inc.	UC Acquisition Corp.
Uni-Care Health Services of Maine, Inc.	Utah CVS Pharmacy, LLC
Value Health Care Services LLC	VAPS Acquisition Company, LLC
Vermont CVS Pharmacy, LLC	VHCS Acquisition Sub, LLC
Virginia CVS Pharmacy, LLC	Warm Springs Road CVS, LLC #2928
Washington CVS Pharmacy, LLC	Washington Lamb CVS, LLC #3172
Weber Medical Systems LLC	Wellpartner, LLC
West Virginia CVS Pharmacy, LLC	Westhaven Services Co, LLC
Williamson Drug Company, Incorporated	Wisconsin CVS Pharmacy, LLC
Woodruff Realty Associates, LLC #2085	Woodward Detroit CVS, LLC
Work & Family Benefits, Inc.	WP Smart Holdings, LLC
ZS Acquisition Company, LLC	976 Miami RE, LLC

(2) As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

10. Information Concerning Parent, Subsidiaries, Affiliates, and Other Related Parties

A., B. and C.

The Company paid \$2,450,000 as an ordinary dividend to its parent on November 16, 2017. The Maine Department approved this distribution on November 6, 2017. The Company did not pay any dividends in 2018. The Company did not receive any capital contributions in 2018 or 2017.

D. Amounts due to and due from affiliates shown in the accompanying Statutory Statements of Assets and Liabilities, Capital and Surplus and Other Funds include the Company's net receipts and disbursements processed by affiliates and transactions related to its administrative services agreement with Aetna Health Management, LLC ("AHM"), indirectly a wholly-owned subsidiary of Aetna.

At December 31, 2018 and 2017, the Company had the following amounts due to and due from affiliates, which exclude amounts related to pharmacy rebate transactions as discussed more fully in Note 28 and the Company's reinsurance agreement:

	December 31	
	2018	2017
Amounts due to affiliates		
Aetna Health Management, Inc.	\$5,585,165	\$677,428
	\$5,585,165	\$677,428

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

- E. The Company does not have any guarantees or undertakings, written or otherwise at December 31, 2018.
- F. As of and for the years ended December 31, 2018 and 2017, the Company had the following significant transactions with affiliates:

The Company and AHM are parties to an administrative services agreement, under which AHM provides certain administrative services, including accounting and processing of premiums and claims. Under this agreement, the Company remits a percentage of its earned commercial, Medicaid and Medicare premium revenue, as applicable, to AHM as a fee, subject to an annual true-up mechanism as defined in the agreement. Under the agreement, this true-up is due to be settled with the affiliate by April 15th of the following contract year (which is January 1 to December 31 annually). The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

	2018	2017
AHM Administrative service fee	\$9,872,308	\$10,014,917
Current year estimated accrued true-up	(1,263,740)	(125,365)
	<u>\$8,608,568</u>	<u>\$9,889,552</u>

These agreements also provide for interest on all intercompany balances. Interest earned on amounts due from affiliates was \$20,898 in 2018 and \$11,777 in 2017. Interest incurred on amounts due to affiliates was \$15,815 in 2018 and \$10,893 in 2017.

The Company is a party to an agreement which enables the Company to receive manufacturers' pharmacy rebates from AHM under which the Company remits a percentage of its earned pharmaceutical rebates to AHM as a fee. The Company earned pharmaceutical rebates of \$4,277,776 and \$3,060,250, which were recorded as a reduction of medical costs, in 2018 and 2017, respectively. The Company was charged \$407,892 and \$306,025, which were recorded as administrative expenses, for these services in 2018 and 2017, respectively. At December 31, 2018 and 2017, the Company reported \$492,550 and \$267,843, respectively, as amounts due from AHM related to the pharmaceutical rebates which were reflected in health care and other amounts receivable. The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

The amounts reported on the Underwriting and Investment Exhibit, Part 3 represent the expenses incurred under the terms of the administrative agreement, allocated to the Company in accordance SSAP No. 70 - *Allocation of Expenses* ("SSAP No. 70"). SSAP No. 70 states "shared expenses, including expenses under the terms of a management contract, shall be apportioned to the entities incurring the expense as if the expense had been paid solely by the incurring entity. The apportionment shall be completed based upon specific identification to the entity incurring the expense. Where specific identification is not feasible, apportionment shall be based upon pertinent factors or ratios." The Company allocates these expenses based upon a percentage calculated using actual general and administrative expenses incurred by AHM and AMA.

The Company has an insolvency agreement with Aetna Health Insurance Company ("AHIC"), a wholly-owned subsidiary of Aetna. This agreement provides that in the event that the Company ceases operations or becomes insolvent, AHIC will continue to pay benefits for any members confined as inpatients on the date of insolvency until their discharge. This agreement also provides that AHIC will continue benefits for any member until the end of the contract period for which premium has been paid. AHIC will also make available to members, for a period of thirty-one days, replacement insurance policies.

As explained in Note 1, the Company participates in a tax sharing agreement with Aetna and Aetna's other subsidiaries. All federal income tax receivables/payables are due from/due to Aetna.

The Company has a guaranty agreement with Aetna. The agreement provides that the Company will maintain a minimum capital and surplus as required by law and any additional surplus the Superintendent of the Maine Department may require so that the Company's surplus is reasonable in relation to its outstanding liabilities. The Company is obligated to maintain the minimum capital and surplus in funds and investments which are admitted assets. The Company will maintain this minimum capital and surplus so long as it has any obligations to enrollees.

- G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is CVS Health.
- H. At December 31, 2018, the Company did not own shares of any upstream intermediate of CVS Health.

- I. At December 31, 2018, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity that exceeded 10% of the Company's admitted assets.
- J. At December 31, 2018, the Company did not hold any investments in any impaired SCA entity.
- K. At December 31, 2018, the Company did not hold any investments in any foreign insurance subsidiaries.
- L. At December 31, 2018, the Company did not hold any investments in a downstream noninsurance holding company.
- M and N.

At December 31, 2018, the Company did not have any investments in an insurance SCA

11. Debt

- A. The Company did not have any items related to debt, including capital notes at December 31, 2018.
- B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2018.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2018 or 2017.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

- (1) The Company had 1,000,000 shares of common capital stock authorized, issued and outstanding with a par value of \$1 per share at December 31, 2018 and 2017.
- (2) The Company had no shares of preferred stock issued and outstanding at December 31, 2018 and 2017.
- (3) Dividend Restrictions

Under the laws of the State of Maine, the Company shall not pay any extraordinary dividend or make any other extraordinary distribution until sixty days after the Maine Department has received notice of the declaration thereof and has not within such period disapproved such payment or the Maine Department has approved such payment within such sixty day period. An extraordinary dividend or distribution includes any dividend or distribution that exceeds the greater of: 10% of such insurer's surplus as regards policyholders as of December 31st of the preceding year; or the net gain from operations for the twelve month period ending December 31st of the preceding year. Ordinary dividends are ultimately limited to earned surplus.

The Company may make a non-extraordinary dividend with prior notification to the Maine Department within five business days following the declaration of any non-extraordinary dividend and at least ten days prior to the payment of any non-extraordinary dividend.

In addition, any dividend or distribution declared at any time within five years following any acquisition of control of a domestic insurer or by any person controlling that insurer is an extraordinary dividend if it has not been approved by a number of continuing directors equal to a majority of the continuing directors in office immediately preceding the acquisition of control.

- (4) The Company did not pay any dividends in 2018. The Company paid \$2,450,000 as an ordinary dividend to its parent on November 16, 2017. The Maine Department approved this distribution on November 6, 2017.
- (5) At December 31, 2018 and 2017, the portion of the Company's profits that may be paid as ordinary dividends to stockholders was \$5,247,705 and \$4,588,855, respectively.
- (6) There were no restrictions placed on the Company's surplus, including for whom the surplus was being held at December 31, 2018 or 2017, except as noted in Note 21.

- (7) Not applicable to the Company.
- (8) The Company did not hold any stock for any special purposes at December 31, 2018 or 2017.
- (9) Changes in the balances of special surplus funds from the prior year are due to the accrual of estimated ACA health insurer fees reclassified from unassigned funds or surplus to aggregate write-ins for special surplus funds as discussed more fully in Note 1.C and Note 22.
- (10) At December 31, 2018 and 2017, there were no unassigned funds that was represented or reduced by unrealized gains and losses.
- (11) The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2018 or 2017.
- (12) The Company did not participate in any quasi-reorganizations during the statement year.
- (13) The Company did not participate in any quasi-reorganizations in the past 10 years.

14. Liabilities, Contingencies and Assessments

- A. The Company did not have any contingent commitments at December 31, 2018 or 2017.
- B. The Company did not have any contingent assessments at December 31, 2018 or 2017.
- C. The Company did not have any gain contingencies at December 31, 2018 or 2017.
- D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2018 or 2017.
- E. The Company did not have any joint and several liability arrangements at December 31, 2018 or 2017.
- F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

The Company has coverage for certain litigation exposures (\$10,000,000 per claim and in the aggregate including defense costs) through an unaffiliated insurance company.

15. Leases

The Company did not have any material lease obligations at December 31, 2018 or 2017.

16. Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2018 or 2017.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

- (1) The Company did not have any transfers of receivables as sales for the years ending December 31, 2018 and 2017.

B. Transfer and Servicing of Financial Assets

- (1) The Company's policy for requiring collateral or other security for security lending transactions as required in SSAP No. 103R is discussed in Note 1. Excludes repurchase and reverse repurchase transactions as discussed in Notes 5.F. through 5.I. The Company did not have any loaned securities at December 31, 2018 and 2017.

(2) and (3)

The Company did not have any servicing assets or liabilities at December 31, 2018 or 2017.

- (4) The Company did not have any securitized financial assets at December 31, 2018 or 2017.
- (5) The Company did not have any transfers of financial assets accounted for as secured borrowing at December 31, 2018 or 2017.
- (6) The Company did not have any transfers of receivables with recourse at December 31, 2018 or 2017.
- (7) The Company did not have any dollar repurchase or reverse repurchase agreements at December 31, 2018 or 2017.

C. Wash Sales

- (1) The Company did not have any wash sales for the years ending December 31, 2018 or 2017.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

- A. The Company did not serve as an Administrative Services Only for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2018.
- B. The Company did not serve as an Administrative Services Contract (ASC) plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2018.
- C. Medicare or other similarly structured cost based reimbursement contract

The Company reports items related to its Medicare product offerings due from (to) CMS as amounts receivable relating to uninsured plans or liability for amounts held under uninsured plans on the Statutory Statements of Assets, Liabilities, Capital and Surplus, as per SSAP No. 47 - *Uninsured Plans*. At December 31, 2018, the Company had low-income subsidy (cost sharing portion) and CMS coverage gap discount receivables of \$252,714 and reinsurance payment payables and low-income subsidy (cost sharing portion) payable of \$431. At December 31, 2017, the Company had low-income subsidy (cost sharing portion) receivables of \$117,884 and CMS coverage gap discount and reinsurance payment payables of \$293,744.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2018 and 2017.

20. Fair Value Measurements

A. and B.

Certain of the Company's financial instruments are measured at fair value in the financial statements. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by U.S. generally accepted accounting principles. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:

- **Level 1** – Unadjusted quoted prices for identical assets or liabilities in active markets.
- **Level 2** – Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
- **Level 3** – Developed from unobservable data, reflecting the Company's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using

valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

- C. The carrying values and estimated fair values of the Company's financial instruments at December 31, 2018 and 2017 were as follows:

December 31, 2018

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	\$33,168,235	\$33,252,918	\$5,280,694	\$27,887,541			
Total	\$33,168,235	\$33,252,918	\$5,280,694	\$27,887,541	—	—	—

December 31, 2017

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	\$25,207,582	\$24,957,930	\$11,285,019	\$13,922,563			
Total	\$25,207,582	\$24,957,930	\$11,285,019	\$13,922,563	—	—	—

The valuation methods and assumptions used by the Company in estimating the fair value of debt securities are discussed in Note 1.

There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2018 or 2017. There were no transfers between the Company's Level 1 or 2 financial assets during 2018 or 2017.

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

- D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.

21. Other Items

A. Unusual or Infrequent Items

The Company did not have any unusual or infrequent items for the years ended December 31, 2018 and 2017.

B. Troubled Debt Restructuring

The Company did not have any troubled debt restructuring in the years ended December 31, 2018 and 2017.

C. Other Disclosures

(1) Minimum Capital and Surplus

Under the laws of the State of Maine, the Company is required to maintain a minimum capital and surplus equal to the greater of (1) \$1,000,000; (2) 2% of the annual premium revenues as reported by the Company on its most recent annual financial statement filed with the Superintendent for the first \$150,000,000 of premium reported and 1% of the annual premium in excess of the first \$150,000,000 of premium reported; (3) an amount equal to the sum of three months of uncovered health care expenditures as reported on the financial statement covering the Company's immediately preceding

fiscal year as filed with the superintendent; or (4) an amount equal to the sum of 8% of the annual health care expenditures, except those paid on a capitated basis as reported on the financial statement covering the Company's immediately preceding fiscal year as filed with the superintendent. At December 31, 2018 and 2017, the Company's capital and surplus exceeded all such requirements.

The NAIC and the State of Maine adopted risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of the company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2018 and 2017, the Company had capital and surplus that exceeded the highest threshold specified by the RBC rules.

(2) Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, "Health Care Reform" or the "ACA"), has made broad-based changes to the U.S. health care system. If the ACA is not further amended, repealed or replaced, certain of its components will continue to be phased in until 2022. While the Company anticipates continued efforts in 2019 and beyond to invalidate, modify, repeal or replace Health Care Reform, the Company expects aspects of Health Care Reform to continue to significantly impact the Company's business operations and financial results, including pricing, medical benefit ratios ("MBRs") and the geographies in which the Company's products are available.

While most of the significant aspects of Health Care Reform became effective during or prior to 2014, parts of Health Care Reform continue to evolve through the promulgation of executive orders, regulations and guidance as well as ongoing litigation. Additional changes to Health Care Reform and those regulations and guidance at the federal and/or state level are likely, and those changes are likely to be significant. Growing state and federal budgetary pressures make it more likely that any changes, including changes at the state level in response to changes to, or invalidation, repeal or replacement of, Health Care Reform and/or changes in the funding levels and/or payment mechanisms of federally supported benefit programs, will be adverse to us. For example, if any elements of Health Care Reform are invalidated or repealed at the federal level, the Company expects that some states would seek to enact similar requirements, such as prohibiting pre-existing condition exclusions, prohibiting rescission of insurance coverage, requiring coverage for dependents up to age 26, requiring guaranteed renewability of insurance coverage and prohibiting lifetime limits on insurance coverage.

Potential repeal of Health Care Reform, ongoing legislative, regulatory and administrative policy changes to Health Care Reform, the results of congressional and state level elections, the December 2018 U.S. District Court decision invalidating Health Care Reform and other pending litigation challenging aspects of the law or funding for the law and federal budget negotiations continue to create uncertainty about the ultimate impact of Health Care Reform. The pending litigation challenging Health Care Reform includes challenges by various states of the federal government's decision to curtail payments related to the Cost-Sharing Subsidy Program. The time frame for conclusion and final outcome and ultimate impact of this litigation are uncertain. Given the inherent difficulty of foreseeing the nature and scope of future changes to Health Care Reform and how states, businesses and individuals will respond to those changes, the Company cannot predict the impact on it of future changes to Health Care Reform. It is reasonably possible that invalidation, repeal or replacement of or other changes to Health Care Reform and/or states' responses to such changes, in the aggregate, could have a significant adverse effect on the Company's businesses, financial results and cash flows.

(3) Medicare

The Company's Medicare Advantage and Standalone Prescription Drug Plan ("PDP") products are heavily regulated by CMS. The regulations and contractual requirements applicable to the Company and other private participants in Medicare programs are complex, expensive to comply with and subject to change. For example, in the second quarter of 2014, CMS issued a final rule implementing the Health Care Reform requirements that Medicare Advantage and PDP plans report and refund to CMS overpayments that those plans receive from CMS. The precise interpretation, impact and legality of this rule are not clear and are subject to pending litigation. Payments the Company receives from CMS for its Medicare Advantage and PDP businesses also are subject to risk adjustment based on the health status of the individuals enrolled. Elements of that risk adjustment mechanism continue to be challenged by the United States Department of Justice, the OIG and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions,

could materially affect the fairness of the Company's Medicare reimbursement, require the Company to raise prices or reduce the benefits offered to Medicare beneficiaries, and potentially limit the Company's (and the industry's) participation in the Medicare program.

The Company has invested significant resources to comply with Medicare standards, and its Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company's Medicare or Medicare-Medicaid demonstration (historically known as "dual eligible") plans, exclude the Company from participating in one or more Medicare or dual eligible programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS regulations or its Medicare contractual requirements.

- D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2018 or 2017.
- E. The Company did not have any transferable and non-transferable state tax credits for the years ending December 31, 2018 or 2017.
- F. The Company did not have any subprime mortgage related risk exposures at December 31, 2018 or 2017.
- G. The Company did not have any retained assets at December 31, 2018 or 2017.
- H. The Company did not have any insurance-linked securities ("ILS") contracts at December 31, 2018 or 2017.

22. Events Subsequent

A. Type I - Recognized Subsequent Events

Subsequent events have been considered through February 27, 2019 for the statutory statement issued on March 1, 2019.

The Company had no known reportable recognized subsequent events.

B. Type II - Nonrecognized Subsequent Events

Subsequent events have been considered through February 27, 2019 for the statutory statement issued on March 1, 2019.

As discussed in Note 1, in January 2018, the HIF was suspended for 2019. As a result, there is no annual health insurance industry fee payable on September 30, 2019 and there are no amounts reflected in the Company's aggregate write-ins for special surplus funds related to this payable at December 31, 2018 as a result. There is also no resulting impact to the Company's RBC to assess as of December 31, 2018 as a result of this suspension.

In January 2018, the annual fee was suspended for 2019.

	Current Year	Prior Year
A. Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the Federal Affordable Care Act (YES/NO)?	YES	
B. ACA fee assessment payable for the upcoming year	—	1,564,000
C. ACA fee assessment paid	\$1,563,536	
D. Premium written subject to ACA 9010 assessment	\$67,115,396	79,227,901
E. Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14)	\$22,575,874	
F. Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	\$22,575,874	
G. Authorized Control Level (Five-Year Historical Line 15)	\$2,473,231	
H. Would reporting the ACA assessment as of Dec. 31, 2017 have triggered an RBC action level (YES/NO)?	NO	

23. Reinsurance

Effective April 1, 2014, the Company entered into a quota share reinsurance agreement with Fresenius Medical Care Reinsurance Company (Cayman) LTD ("Fresenius"), an affiliate of Fresenius Medical Care Holdings, Inc.,

covering Medicare Advantage Plans. Under this agreement, the Company will cede to Fresenius and Fresenius shall reinsure 100% of eligible expenses incurred per program participant per agreement year. The Company paid reinsurance premiums of \$210,016 in 2018 and \$200,158 in 2017 related to this agreement. The Company realized net reinsurance recoveries of \$260,763 in 2018 and \$204,550 in 2017.

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

- (1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?
Yes () No (X)

If yes, give full details.

- (2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?
Yes (X) No ()

If yes, give full details.

Fresenius is located in the Cayman Islands and is an affiliate of Fresenius Medicare Care Holdings, Inc. (not primarily engaged in the insurance business).

Section 2 – Ceded Reinsurance Report – Part A

- (1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than nonpayment of premium or other similar credit?
Yes () No (X)

- a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate.
\$ N/A.

- b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement?
\$ N/A.

- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?
Yes () No (X)

If yes, give full details.

Section 3 – Ceded Reinsurance Report – Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the insurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate.
\$ N/A

- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?
Yes () No (X)

If yes, what is the amount of reinsurance credit, whether an asset or a reduction of liability, taken for such new agreements or amendments? \$ N/A

- B. The Company did not have uncollectible reinsurance at December 31, 2018.
- C. The Company did not have any commutation of ceded reinsurance at December 31, 2018.
- D. The Company's certified reinsurer's rating has not been downgraded or its status subject to revocation at December 31, 2018.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

- A. Through annual contracts with CMS, the Company offers HMO plans for Medicare-eligible individuals through the Medicare Advantage program. Members typically receive enhanced benefits over standard Medicare fee-for-service coverage, including reduced cost-sharing for preventative care, vision and other non-Medicare services. Members also typically receive coverage for certain prescription drugs, usually subject to a deductible, co-insurance and/or co-payment. The revenues ultimately received by the Company for each member are based on that member's health status and demographic characteristics, as determined via the CMS risk adjustment process, under which the Company regularly submits risk adjustment data to CMS. As such, at December 31, 2018, the Company records a receivable for future revenues that it expects to receive from CMS in the third quarter of 2019, after the final reconciliation of risk adjustment data for contract year 2018 is complete. The Company estimates this receivable by taking into account risk adjustment data for contract year 2018 submitted to CMS prior to December 31, 2018, as well as its estimate of the impact of risk adjustment data for contract year 2018 that will be submitted prior to the appropriate regulatory deadline in early 2019. These amounts are recognized in 2018 as premiums under contracts subject to redetermination. In addition, the Company's Medicare Advantage contracts are subject to retrospective rating provisions under which the Company and CMS share in amounts above and below agreed-upon target medical benefit ratios.
- B. These accrued retrospective premiums, if any, are recorded through premiums and are estimated based on calculations that compare the Company's expected financial results for the contract against the appropriate medical benefit ratio target. The Company had net premiums written of \$53,807,440 and \$55,191,307 related to its agreements with CMS for the years ending December 31, 2018 and 2017, respectively, representing 80% for 2018 and 70% for 2017 of total premium revenue. The Company had net premiums receivable of \$2,160,585 and \$1,977,782 related to its agreements with CMS at December 31, 2018 and 2017 respectively, representing 95% for 2018 and 90% for 2017 of total premiums receivable.

C. Contracts Subject to Retrospective Rating Features

The Company did not have any contracts subject to retrospective rating features December 31, 2018 and 2017.

D. Medical loss ratio rebates required pursuant to the Public Health Service Act

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual MLR were not met in the prior year. The Company's results for full-year

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

	1 Individual	2 Small Group Employer	3 Large Group Employer	4 Other Categories with rebates	5 Total
Prior Reporting Year					
(1) Medical Loss Ratio Rebates Incurred	—	\$9,542	—	1,228,774	\$1,238,316
(2) Medical Loss Ratio Rebates Paid	—	\$—	—	—	\$—
(3) Medical Loss Ratio Rebates Unpaid	—	9,542	—	1,228,774	1,238,316
(4) Plus reinsurance assumed amounts					—
(5) Less reinsurance ceded amounts					—
(6) Rebates Unpaid net of reinsurance					1,238,316
Current Reporting Year-to-Date					
(1) Medical Loss Ratio Rebates Incurred	—	\$1,300,745	—	(\$1,218,278)	\$82,467
(2) Medical Loss Ratio Rebates Paid	—	—	—	—	—
(3) Medical Loss Ratio Rebates Unpaid	—	\$1,310,287	—	\$10,496	\$1,320,783
(4) Plus reinsurance assumed amounts					—
(5) Less reinsurance ceded amounts					—
(6) Rebates Unpaid net of reinsurance					\$1,320,783

E. Risk Sharing Provisions of the Affordable Care Act (ACA)

- (1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)? Yes [X] No []
- (2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year

	Amount
a. Permanent ACA Risk Adjustment Program	
Assets	
1. Premium adjustments receivable due to ACA Risk Adjustment	\$—
Liabilities (including high-risk pool payments)	
2. Risk adjustment user fees payable for ACA Risk Adjustment	(\$1,147)
3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool payments)	(\$359,329)
Operations (Revenue & Expense)	
4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	\$56,220
5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	\$620
b. Transitional ACA Reinsurance Program	
Assets	
1. Amounts recoverable for claims paid due to ACA Reinsurance	\$527
2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)	
3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	
Liabilities	
4. Liabilities for contributions payable due to ACA Reinsurance – not reported as ceded premium	
5. Ceded reinsurance premiums payable due to ACA Reinsurance	
6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance	
Operations (Revenue & Expense)	
7. Ceded reinsurance premiums due to ACA Reinsurance	
8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$0
9. ACA Reinsurance contributions – not reported as ceded premium	
c. Temporary ACA Risk Corridors Program	
Assets	
1. Accrued retrospective premium due to ACA Risk Corridors	
Liabilities	
2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	
Operations (Revenue & Expense)	
3. Effect of ACA Risk Corridors on net premium income (paid/received)	
4. Effect of ACA Risk Corridors on change in reserves for rate credits	

- (3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year balance.

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

	Accrued During the Prior Year on Business Written		Received or Paid as of the Current Year on Business		Differences		Adjustments			Unsettled Balances as of the Reporting Date	
	Before December 31 of the Prior Year		Written Before December 31 of the Prior Year		Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. Permanent ACA Risk Adjustment Program											
1. Premium adjustments receivable (including high-risk)	\$11,622		\$395,130		(383,508)	—	\$383,509		A	1	—
2. Premium adjustments (payable) (including high-risk)		\$781,458		\$861,857	—	(\$80,399)		\$80,399	B	—	—
3. Subtotal ACA Permanent Risk Adjustment Program	11,622	\$781,458	395,130	\$861,857	(383,508)	(\$80,399)	383,509	\$80,399		1	—
b. Transitional ACA Reinsurance Program											
1. Amounts recoverable for claims paid	\$15,734		\$15,207		\$527	—			C	\$527	—
2. Amounts recoverable for claims unpaid (contra liability)					—	—			D	—	—
3. Amounts receivable relating to uninsured plans					—	—			E	—	—
4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium					—	—			F	—	—
5. Ceded reinsurance premiums payable					—	—			G	—	—
6. Liability for amounts held under uninsured plans					—	—			H	—	—
7. Subtotal ACA Transitional Reinsurance Program	\$15,734	\$0	\$15,207	\$0	\$527	—	\$0	—		\$527	—
c. Temporary ACA Risk Corridors Program											
1. Accrued retrospective premium					—	—			I	—	—
2. Reserve for rate credits or policy experience rating refunds					—	—			J	—	—
3. Subtotal ACA Risk Corridors Program	—	—	—	—	—	—	—	—		—	—
d. Total for ACA Risk Sharing Provisions	\$27,356	\$781,458	\$410,337	\$861,857	(\$382,981)	(\$80,399)	\$383,509	\$80,399		\$528	—

B. Due to updates to the data available to the Company to calculate the risk adjustment.

(4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year

Risk Corridors Program Year	Accrued During the Prior Year on Business Written		Received or Paid as of the Current Year on Business		Differences		Adjustments			Unsettled Balances as of the Reporting Date	
	Before December 31 of the Prior Year		Written Before December 31 of the Prior Year		Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a. 2014											
1. Accrued retrospective premium					—	—			A	—	—
2. Reserve for rate credits or policy experience rating refunds					—	—			B	—	—
b. 2015											
1. Accrued retrospective premium					—	—			C	—	—
2. Reserve for rate credits or policy experience rating refunds					—	—			D	—	—
c. 2016											
1. Accrued retrospective premium					—	—			E	—	—
2. Reserve for rate credits or policy experience rating refunds					—	—			F	—	—
d. Total for Risk Corridors	—	—	—	—	—	—	—	—		—	—

Explanations of Adjustments

- A. Due to updates to the data available to the Company to calculate the risk adjustment.
- B. Due to additional claims run-out after the December 31, 2017 period.

(5) ACA Risk Corridors Receivable as of Reporting Date.

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

		1	2	3	4	5	6
		Estimated Amount to be Filed or Final Amount Filed with CMS	Non-Accrued Amounts for Impairment or Other Reasons	Amounts received from CMS	Asset Balance (Gross of Non-admissions) (1, 2, 3)	Non-admitted Amount	Net Admitted Asset (4 - 5)
a.	2014				—		—
b.	2015				—		—
c.	2016				—		—
d.	Total (a + b + c)	—	—	—	—	—	—

24E(5)d (Column 4) should equal 24E(3)c1 (Column 9)
24E(5)d (Column 6) should equal 24E(2)c1

25. Change in Incurred Claims and Claims Adjustment Expense

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2018 and 2017.

	2018	2017
Balance, January 1	\$ 8,053,229	\$ 8,580,766
Health care receivable	(267,843)	(285,581)
Balance, January 1, net of health care receivable	7,785,386	8,295,185
Incurred related to:		
Current year	\$ 53,388,788	\$ 64,945,775
Prior years	(3,500,974)	(2,236,697)
Total incurred	49,887,814	62,709,078
Paid related to:		
Current year	\$ 48,570,082	\$ 57,521,089
Prior years	3,995,900	5,697,788
Total paid	52,565,982	63,218,877
Balance, December 31, net of health care receivable	\$ 5,107,218	\$ 7,785,386
Health care receivable	492,549	267,843
Balance, December 31	\$ 5,599,767	\$ 8,053,229

In 2018, reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by \$3,500,974 from \$8,053,229 in 2017 to \$4,552,255 in 2018. In 2017, reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by \$2,236,697 from \$8,580,766 in 2016 to \$6,344,069 in 2017. The lower than anticipated health care cost trend rates observed in 2017 and 2017 for claims incurred in 2017 and 2016, respectively, were due to moderating outpatient and physician trends and faster than expected claim payment speed. The Company considers historical trend rates together with knowledge of recent events that may impact current trends when developing estimates of current trend rates. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Historical health care cost trend rates are not necessarily representative of current trends. The Company experienced \$2,232,230 of favorable prior year claim development on retrospectively rated policies, which is included in the net 2017 decrease. However, the business to which it relates is subject to premium adjustments. The Company excluded the impact of the change in health care receivables related to pharmacy rebates from the above roll-forward to conform to NAIC Annual Statement presentation.

Net coordination of benefits are implicit in the claims incurred but not reported calculation and could not be specifically identified.

26. Intercompany Pooling Arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2018 or 2017.

27. Structured Settlements

Not applicable to health entities.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

The Company receives pharmaceutical rebates through an agreement with AHM. AHM has contractual agreements with pharmaceutical companies for rebates, which cover the Company's membership as well as the membership of other Aetna affiliates. The Company receives those rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in first out methodology. At December 31, 2018 and 2017, the Company had pharmaceutical rebate receivables of \$492,550 and \$267,843, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10.

Date	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2018	\$1,037,606	936,251	\$557,100 ¹	\$—	\$—
09/30/2018	\$1,019,403	\$1,039,276	\$1,000,472	\$—	\$—
06/30/2018	\$1,033,776	\$1,054,361	\$1,019,128	\$—	\$—
03/31/2018	\$988,132	\$1,034,499	\$995,138	\$—	\$—
12/31/2017	\$805,351	\$894,339	\$282,373	\$—	\$—
09/30/2017	\$723,338	\$816,734	\$822,878	\$—	\$—
06/30/2017	\$770,151	\$793,495	\$801,982	\$—	\$—
03/31/2017	\$707,737	\$679,653	\$686,000	\$—	\$—
12/31/2016	\$764,227	\$729,862	\$729,862	\$—	\$—
09/30/2016	\$779,817	\$800,356	\$800,356	\$—	\$—
06/30/2016	\$778,031	\$758,137	\$758,137	\$—	\$—
03/31/2016	\$722,094	\$679,569	\$679,569	\$—	\$—

¹ Represents a portion of the estimated rebates for the quarter ending December 31, 2018, which were paid by AHM to the Company prior to December 31, 2018 and invoicing in 2018.

B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2018 or 2017.

29. Participating Policies

The Company did not have any participating policies at December 31, 2018 or 2017.

30. Premium Deficiency Reserves

	December 31, 2018
1. Liability carried for premium deficiency reserves	\$0
2. Date of the most recent evaluation of this liability	12/31/2018
3. Was anticipated investment income utilized in the calculation?	YES

31. Anticipated Salvage and Subrogation

See discussion of hospital and medical costs and claims adjustment expenses and related reserves in Note 1.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES
GENERAL

1.1

Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?
If yes, complete Schedule Y, Parts 1, 1A and 2

Yes ☒ No ☐

1.2

If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent, or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?

Yes ☒ No ☐ N/A ☐

1.3

State Regulating?

Maine

1.4

Is the reporting entity publicly traded or a member of a publicly traded group?

Yes ☒ No ☐

1.5

If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.

0000064803

2.1

Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?

Yes ☐ No ☒

2.2

If yes, date of change:

3.1

State as of what date the latest financial examination of the reporting entity was made or is being made.

12/31/2017

3.2

State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released.

12/31/2013

3.3

State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).

10/30/2015

3.4

By what department or departments?
Maine Bureau of Insurance

3.5

Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?

Yes ☐ No ☐ N/A ☒

3.6

Have all of the recommendations within the latest financial examination report been complied with?

Yes ☐ No ☐ N/A ☒

4.1

During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.11 sales of new business?
4.12 renewals?

Yes ☐ No ☒
Yes ☐ No ☒

4.2

During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.21 sales of new business?
4.22 renewals?

Yes ☐ No ☒
Yes ☐ No ☒

5.1

Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?
If yes, complete and file the merger history data file with the NAIC.

Yes ☐ No ☒

5.2

If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile
.....		

6.1

Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period?

Yes ☐ No ☒

6.2

If yes, give full information:

7.1

Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?

Yes ☐ No ☒

7.2

If yes,
7.21 State the percentage of foreign control; %
7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation or government, manager or attorney in fact).

1 Nationality	2 Type of Entity
.....	

GENERAL INTERROGATORIES

8.1

Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board?

Yes [] No [X]

8.2

If response to 8.1 is yes, please identify the name of the bank holding company.

8.3

Is the company affiliated with one or more banks, thrifts or securities firms?

Yes [] No [X]

8.4

If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1	2	3	4	5	6
Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC

9.

What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?

KPMG LLP, One Financial Plaza, 755 Main Street, Hartford, CT 06103

10.1

Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation?

Yes [] No [X]

10.2

If the response to 10.1 is yes, provide information related to this exemption:

10.3

Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation?

Yes [] No [X]

10.4

If the response to 10.3 is yes, provide information related to this exemption:

10.5

Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws?

Yes [X] No [] N/A []

10.6

If the response to 10.5 is no or n/a, please explain

11.

What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?

Jeffrey J. Drzazgowski, FSA, MAAA; 151 Farmington Avenue, RE2R; Hartford, CT 06156

12.1

Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly?

Yes [] No [X]

12.11

Name of real estate holding company

12.12

Number of parcels involved

12.13

Total book/adjusted carrying value

\$

12.2

If, yes provide explanation:

13.

FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:

13.1

What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?

N/A

13.2

Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located?

Yes [] No []

13.3

Have there been any changes made to any of the trust indentures during the year?

Yes [] No []

13.4

If answer to (13.3) is yes, has the domiciliary or entry state approved the changes?

Yes [] No [] N/A []

14.1

Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards?

Yes [X] No []

(a)

Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

(b)

Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;

(c)

Compliance with applicable governmental laws, rules and regulations;

(d)

The prompt internal reporting of violations to an appropriate person or persons identified in the code; and

(e)

Accountability for adherence to the code.

14.11

If the response to 14.1 is No, please explain:

14.2

Has the code of ethics for senior managers been amended?

Yes [X] No []

14.21

If the response to 14.2 is yes, provide information related to amendment(s).

Through November 28, 2018, senior management was subject to the Aetna Inc. Code of Conduct. Effective with the acquisition of Aetna Inc. by CVS Health Corporation, senior management become subject to the CVS Health Code of Conduct.

14.3

Have any provisions of the code of ethics been waived for any of the specified officers?

Yes [] No [X]

14.31

If the response to 14.3 is yes, provide the nature of any waiver(s).

GENERAL INTERROGATORIES

- 15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List?
- 15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.
- Yes [] No [X]

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount

BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof?
17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof?
18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict with the official duties of such person?
- Yes [X] No []
- Yes [X] No []
- Yes [X] No []

FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)?
- 20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.11 To directors or other officers
- 20.12 To stockholders not officers
- 20.13 Trustees, supreme or grand (Fraternal Only)
- 20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.21 To directors or other officers
- 20.22 To stockholders not officers
- 20.23 Trustees, supreme or grand (Fraternal Only)
- 21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement?
- 21.2 If yes, state the amount thereof at December 31 of the current year:
- 21.21 Rented from others
- 21.22 Borrowed from others
- 21.23 Leased from others
- 21.24 Other
- 22.1 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments?
- 22.2 If answer is yes:
- 22.21 Amount paid as losses or risk adjustment
- 22.22 Amount paid as expenses
- 22.23 Other amounts paid
- 23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement?
- 23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount:
- Yes [] No [X]
- \$
- \$
- \$
- \$
- \$
- \$
- \$
- \$
- \$
- \$
- \$
- \$
- Yes [] No [X]
- Yes [] No [X]
- \$
- \$
- \$
- Yes [] No [X]
- \$

INVESTMENT

- 24.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 24.03)
- 24.02 If no, give full and complete information relating thereto
- 24.03 For security lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided) We are not currently investing in the securities lending program as of 12/31/2018.
- 24.04 Does the Company's security lending program meet the requirements for a conforming program as outlined in the Risk-Based Capital Instructions?
- 24.05 If answer to 24.04 is yes, report amount of collateral for conforming programs.
- 24.06 If answer to 24.04 is no, report amount of collateral for other programs.
- 24.07 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract?
- 24.08 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%?
- 24.09 Does the reporting entity or the reporting entity 's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending?
- Yes [X] No []
-
-
- Yes [] No [] N/A [X]
- \$
- \$
- Yes [] No [] N/A [X]
- Yes [] No [] N/A [X]
- Yes [] No [] N/A [X]

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

GENERAL INTERROGATORIES

24.10 For the reporting entity’s security lending program state the amount of the following as December 31 of the current year:

24.101	Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2.	\$	0
24.102	Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2.	\$	0
24.103	Total payable for securities lending reported on the liability page.	\$	0

25.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity, or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 24.03).

Yes [X] No []

25.2	If yes, state the amount thereof at December 31 of the current year:	25.21 Subject to repurchase agreements	\$	
		25.22 Subject to reverse repurchase agreements	\$	
		25.23 Subject to dollar repurchase agreements	\$	
		25.24 Subject to reverse dollar repurchase agreements	\$	
		25.25 Placed under option agreements	\$	
		25.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	\$	
		25.27 FHLB Capital Stock	\$	
		25.28 On deposit with states	\$	400,899
		25.29 On deposit with other regulatory bodies	\$	
		25.30 Pledged as collateral - excluding collateral pledged to an FHLB	\$	
		25.31 Pledged as collateral to FHLB - including assets backing funding agreements	\$	
		25.32 Other	\$	

25.3 For category (25.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount

26.1 Does the reporting entity have any hedging transactions reported on Schedule DB?

Yes [] No [X]

26.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?

Yes [] No [] N/A [X]

If no, attach a description with this statement.

27.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity?

Yes [] No [X]

27.2 If yes, state the amount thereof at December 31 of the current year.

\$

28. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook?

Yes [X] No []

28.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
State Street Bank and Trust Company	State Street Financial Center; One Lincoln Street; Boston, MA 02111-2900

28.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

28.03 Have there been any changes, including name changes, in the custodian(s) identified in 28.01 during the current year?

Yes [] No [X]

28.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

GENERAL INTERROGATORIES

28.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1 Name of Firm or Individual	2 Affiliation
Kevin J. Casey as Sr. Investment Officer	A.....
.....

28.0597 For those firms/individuals listed in the table for Question 28.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's assets?..... Yes [] No [X]

28.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 28.05, does the total assets under management aggregate to more than 50% of the reporting entity's assets?..... Yes [] No [X]

28.06 For those firms or individuals listed in the table for 28.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name of Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Management Agreement (IMA) Filed
N/A	Kevin J. Casey	-	Not registered
-	-	-	-
.....
.....

29.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [] No [X]

29.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
29.2999 - Total		0

29.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation
.....

30. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1 Statement (Admitted) Value	2 Fair Value	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
30.1 Bonds	27,575,450	27,490,766	(84,684)
30.2 Preferred stocks	0		0
30.3 Totals	27,575,450	27,490,766	(84,684)

30.4 Describe the sources or methods utilized in determining the fair values:
Fair value of long term bonds and preferred stocks are determined based on quoted market prices when available, fair values using valuation methodologies based on available and observable market information, or by using matrix pricing. If quoted market prices are not available, we determine fair value using broker quoted or an internal analysis of each investment's financial performance and cash flow projections. Short-term investments are carried at amortized cost which approximated fair value. The carrying value of cash equivalents approximated fair value.

31.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [X] No []

31.2 If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? Yes [X] No []

31.3 If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:
.....

32.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? Yes [X] No []

32.2 If no, list exceptions:
.....

GENERAL INTERROGATORIES

33.

By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:
a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
b. Issuer or obligor is current on all contracted interest and principal payments.
c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.
Has the reporting entity self-designated 5GI securities?

Yes [] No [X]
34.

By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:
a. The security was purchased prior to January 1, 2018.
b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.
Has the reporting entity self-designated PLGI securities?

Yes [] No [X]

OTHER

35.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?\$4,263

35.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

1 Name	2 Amount Paid
Council for Affordable Quality Healthcare	1,465
.....	

36.1 Amount of payments for legal expenses, if any?\$85,924

36.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1 Name	2 Amount Paid
.....	

37.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any?\$

37.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1 Name	2 Amount Paid
.....	

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1

Does the reporting entity have any direct Medicare Supplement Insurance in force?

Yes [] No [X]

1.2

If yes, indicate premium earned on U.S. business only.

\$

1.3

What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit?

\$

1.31

Reason for excluding

1.4

Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above

\$

1.5

Indicate total incurred claims on all Medicare Supplement Insurance.

\$

0

1.6

Individual policies:

Most current three years:

1.61

Total premium earned

\$

0

1.62

Total incurred claims

\$

0

1.63

Number of covered lives

0

All years prior to most current three years:

1.64

Total premium earned

\$

0

1.65

Total incurred claims

\$

0

1.66

Number of covered lives

0

1.7

Group policies:

Most current three years:

1.71

Total premium earned

\$

0

1.72

Total incurred claims

\$

0

1.73

Number of covered lives

0

All years prior to most current three years:

1.74

Total premium earned

\$

0

1.75

Total incurred claims

\$

0

1.76

Number of covered lives

0

2.

Health Test:

1

Current Year

2

Prior Year

2.1

Premium Numerator

66,905,380

79,027,743

2.2

Premium Denominator

66,905,379

79,027,743

2.3

Premium Ratio (2.1/2.2)

1.000

1.000

2.4

Reserve Numerator

8,917,081

10,147,018

2.5

Reserve Denominator

8,917,081

10,147,018

2.6

Reserve Ratio (2.4/2.5)

1.000

1.000

3.1

Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits?

Yes [] No [X]

3.2

If yes, give particulars:

4.1

Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency?

Yes [X] No []

4.2

If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered?

Yes [] No [X]

5.1

Does the reporting entity have stop-loss reinsurance?

Yes [] No [X]

5.2

If no, explain:
The Company does not have stop-loss reinsurance.

5.3

Maximum retained risk (see instructions)

5.31

Comprehensive Medical

\$

5.32

Medical Only

\$

5.33

Medicare Supplement

\$

5.34

Dental & Vision

\$

5.35

Other Limited Benefit Plan

\$

5.36

Other

\$

6.

Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:
Provider contracts contain hold harmless and continuity of coverage provisions. In addition, the HMO maintains an insolvency protection agreement with an affiliate of the HMO.

7.1

Does the reporting entity set up its claim liability for provider services on a service date basis?

Yes [X] No []

7.2

If no, give details

8.

Provide the following information regarding participating providers:

8.1

Number of providers at start of reporting year

11,690

8.2

Number of providers at end of reporting year

14,925

9.1

Does the reporting entity have business subject to premium rate guarantees?

Yes [] No [X]

9.2

If yes, direct premium earned:

9.21

Business with rate guarantees between 15-36 months.

\$

9.22

Business with rate guarantees over 36 months

\$

GENERAL INTERROGATORIES

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? Yes [X] No []

10.2 If yes:

10.21 Maximum amount payable bonuses.....\$1,452,537

10.22 Amount actually paid for year bonuses.....\$1,218,657

10.23 Maximum amount payable withholds.....\$

10.24 Amount actually paid for year withholds.....\$

11.1 Is the reporting entity organized as:

11.12 A Medical Group/Staff Model, Yes [] No [X]

11.13 An Individual Practice Association (IPA), or, . Yes [X] No []

11.14 A Mixed Model (combination of above)? Yes [] No [X]

11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements? Yes [X] No []

11.3 If yes, show the name of the state requiring such minimum capital and surplus. Maine

11.4 If yes, show the amount required.\$4,946,462

11.5 Is this amount included as part of a contingency reserve in stockholder's equity? Yes [] No [X]

11.6 If the amount is calculated, show the calculation

See Notes to Financial Statement - Note 21, Other Items, C., Other Disclosures.

12. List service areas in which reporting entity is licensed to operate:

1
Name of Service Area
The Company is licensed in every county in the State of Maine.
.....

13.1 Do you act as a custodian for health savings accounts? Yes [] No [X]

13.2 If yes, please provide the amount of custodial funds held as of the reporting date.\$

13.3 Do you act as an administrator for health savings accounts? Yes [] No [X]

13.4 If yes, please provide the balance of funds administered as of the reporting date.\$

14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? Yes [] No [] N/A [X]

14.2 If the answer to 14.1 is yes, please provide the following:

1	2 NAIC Company Code	3 Domiciliary Jurisdiction	4 Reserve Credit	Assets Supporting Reserve Credit		
				5 Letters of Credit	6 Trust Agreements	7 Other
Company Name						
.....						

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):

15.1 Direct Premium Written\$

15.2 Total Incurred Claims\$

15.3 Number of Covered Lives

*Ordinary Life Insurance Includes
Term(whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary gurarantee)
Universal Life (with or without secondary gurarantee)
Variable Universal Life (with or without secondary gurarantee)

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? Yes [] No [X]

16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? Yes [] No [X]

FIVE-YEAR HISTORICAL DATA

	1 2018	2 2017	3 2016	4 2015	5 2014
Balance Sheet (Pages 2 and 3)					
1. Total admitted assets (Page 2, Line 28)	37,243,971	28,861,178	27,647,958	26,219,633	27,908,162
2. Total liabilities (Page 3, Line 24)	14,668,097	11,314,022	12,125,136	13,568,143	12,238,314
3. Statutory minimum capital and surplus requirement	4,946,462	5,758,968	5,947,942	6,461,244	8,112,440
4. Total capital and surplus (Page 3, Line 33)	22,575,874	17,547,156	15,522,822	12,651,490	15,669,848
Income Statement (Page 4)					
5. Total revenues (Line 8)	66,818,063	77,806,626	75,281,057	80,083,644	104,717,067
6. Total medical and hospital expenses (Line 18)	49,887,814	61,400,790	63,020,996	69,119,757	91,062,950
7. Claims adjustment expenses (Line 20)	1,318,543	1,308,288	1,237,316	1,267,211	1,591,423
8. Total administrative expenses (Line 21)	9,390,154	9,311,687	8,985,473	10,211,496	12,084,100
9. Net underwriting gain (loss) (Line 24)	6,221,552	5,785,861	2,698,233	(1,175,781)	2,098,187
10. Net investment gain (loss) (Line 27)	709,833	603,560	550,925	550,092	718,033
11. Total other income (Lines 28 plus 29)	0	0	0	0	0
12. Net income or (loss) (Line 32)	5,247,706	4,588,855	2,502,764	(1,188,052)	2,559,654
Cash Flow (Page 6)					
13. Net cash from operations (Line 11)	3,371,911	3,632,309	4,252,055	1,689,624	(2,650,769)
Risk-Based Capital Analysis					
14. Total adjusted capital	22,575,874	17,547,156	15,522,822	12,651,490	15,669,848
15. Authorized control level risk-based capital	2,473,231	2,879,484	2,973,971	3,230,622	4,056,220
Enrollment (Exhibit 1)					
16. Total members at end of period (Column 5, Line 7)	8,297	11,167	11,242	11,729	12,582
17. Total members months (Column 6, Line 7)	104,140	133,929	133,033	137,371	205,808
Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Lines 18 plus Line 19)	74.7	78.9	83.7	86.3	87.0
20. Cost containment expenses	1.3	1.4	1.4	1.2	1.1
21. Other claims adjustment expenses	0.6	0.2	0.3	0.4	0.4
22. Total underwriting deductions (Line 23)	90.7	92.6	96.4	101.5	98.0
23. Total underwriting gain (loss) (Line 24)	9.3	7.4	3.6	(1.5)	2.0
Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 13, Col. 5)	4,463,639	5,935,160	6,049,361	7,499,933	7,978,034
25. Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]	7,696,770	8,190,532	8,146,915	7,386,048	9,293,699
Investments In Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)				0	0
27. Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)				0	0
28. Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)				0	0
29. Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30. Affiliated mortgage loans on real estate					
31. All other affiliated					
32. Total of above Lines 26 to 31	0	0	0	0	0
33. Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors? Yes [] No []

If no, please explain:

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories										
		1	Direct Business Only							
		Active Status (a)	2	3	4	5	6	7	8	9
States, etc.			Accident & Health Premiums	Medicare Title XVIII	Medicaid Title XIX	Federal Employees Health Benefits Plan Premiums	Life & Annuity Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 7	Deposit-Type Contracts
1.	Alabama	AL	N						0	
2.	Alaska	AK	N						0	
3.	Arizona	AZ	N						0	
4.	Arkansas	AR	N						0	
5.	California	CA	N						0	
6.	Colorado	CO	N						0	
7.	Connecticut	CT	N						0	
8.	Delaware	DE	N						0	
9.	District of Columbia	DC	N						0	
10.	Florida	FL	N						0	
11.	Georgia	GA	N						0	
12.	Hawaii	HI	N						0	
13.	Idaho	ID	N						0	
14.	Illinois	IL	N						0	
15.	Indiana	IN	N						0	
16.	Iowa	IA	N						0	
17.	Kansas	KS	N						0	
18.	Kentucky	KY	N						0	
19.	Louisiana	LA	N						0	
20.	Maine	ME	L	13,097,940	54,017,456				67,115,396	
21.	Maryland	MD	N						0	
22.	Massachusetts	MA	N						0	
23.	Michigan	MI	N						0	
24.	Minnesota	MN	N						0	
25.	Mississippi	MS	N						0	
26.	Missouri	MO	N						0	
27.	Montana	MT	N						0	
28.	Nebraska	NE	N						0	
29.	Nevada	NV	N						0	
30.	New Hampshire	NH	N						0	
31.	New Jersey	NJ	N						0	
32.	New Mexico	NM	N						0	
33.	New York	NY	N						0	
34.	North Carolina	NC	N						0	
35.	North Dakota	ND	N						0	
36.	Ohio	OH	N						0	
37.	Oklahoma	OK	N						0	
38.	Oregon	OR	N						0	
39.	Pennsylvania	PA	N						0	
40.	Rhode Island	RI	N						0	
41.	South Carolina	SC	N						0	
42.	South Dakota	SD	N						0	
43.	Tennessee	TN	N						0	
44.	Texas	TX	N						0	
45.	Utah	UT	N						0	
46.	Vermont	VT	N						0	
47.	Virginia	VA	N						0	
48.	Washington	WA	N						0	
49.	West Virginia	WV	N						0	
50.	Wisconsin	WI	N						0	
51.	Wyoming	WY	N						0	
52.	American Samoa	AS	N						0	
53.	Guam	GU	N						0	
54.	Puerto Rico	PR	N						0	
55.	U.S. Virgin Islands	VI	N						0	
56.	Northern Mariana Islands	MP	N						0	
57.	Canada	CAN	N						0	
58.	Aggregate other alien	OT	XXX	0	0	0	0	0	0	0
59.	Subtotal	XXX	13,097,940	54,017,456	0	0	0	0	67,115,396	0
60.	Reporting entity contributions for Employee Benefit Plans	XXX							0	
61.	Total (Direct Business)	XXX	13,097,940	54,017,456	0	0	0	0	67,115,396	0
DETAILS OF WRITE-INS										
58001.	XXX								
58002.	XXX								
58003.	XXX								
58998.	Summary of remaining write-ins for Line 58 from overflow page	XXX	0	0	0	0	0	0	0	0
58999.	Totals (Lines 58001 through 58003 plus 58998)(Line 58 above)	XXX	0	0	0	0	0	0	0	0


(a) Active Status Counts:
L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG.....1
E - Eligible - Reporting entities eligible or approved to write surplus lines in the state.....0
N - None of the above - Not allowed to write business in the state.....56
R - Registered - Non-domiciled RRGs.....0
Q - Qualified - Qualified or accredited reinsurer.....0

(b) Explanation of basis of allocation by states, premiums by state, etc.
'Allocation by state is based on the employer group's state of domicile

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



This organizational chart reflects the insurance entity reporting system and identifies the relationship between the ultimate parent and all member insurers. The ultimate controlling company is a Fortune 7 company with numerous subsidiaries, the majority of which do not interact with the insurance entities.

(1) Insurers/HMO's

Percentages are rounded to the nearest whole percent and based on ownership of voting rights.


Double borders indicate entity has subsidiaries shown on the same page.

Bold borders indicate entity has subsidiaries shown on a separate page.

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




* PHPSNE Parent Corporation is also 45% owned by third parties.

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



*1 PT. Aetna Global Benefits Indonesia is also 20% owned by Suhatsyah Rival, Aetna's Nominee.

*2 Aetna Global Benefits (Middle East) LLC is also 51% is owned by Euro Gulf LLC, Aetna's Nominee.

*3 Indian Health Organisation Private Limited is 0.019857% owned by Aetna Global Benefits (Asia Pacific) and 99.980143% owned by Aetna Global Benefits (Singapore) PTE. LTD.

*4 PT Asuransi Aetna Asia is also 23% owned by PT Asuransi Central Asia.

*5 Tianjin An Hai Tai Hua Medical Information Technology Co., Ltd is also 50% owned by Tianjin Hai Tai Group Co., Ltd

*6 Virtual Home Health Care L.L.C. is also 51% owned by CBD Commercial Brokers LLC, Aetna's Nominee

*7 Health Care Management Co. Ltd. is also owned by Aetna Global Benefits (Bermuda) Limited (1 share).

*8 Aetna Health Insurance (Thailand) Public Company Limited is also owned by Aetna Global Benefits (Bermuda) Limited (1 share), Mr. Sansanapongpherchar (1 Share), Mr. Jitphasong Itsaraphakded (1 Share); Mrs. Suphee Wattana (1 Share); and Mr. Buncha Tampragom (1 Share)

*9 Aetna Holdings (Thailand) Limited is also 51% owned by Mr. Paiboon Sutantivorakoon plus Aetna Benefits (Bermuda) Limited owns 1 share.


*10 Minor Health Enterprise Co, Ltd is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited

*11 Aetna Services (Thailand) Limited is also (1 share) owned by Aetna Global Benefits (Bermuda) Limited and (1 share) owned by Aetna Global Holdings Limited

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)


SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




*100% owned through Aetna's nominees

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).

*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

*3 Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.


*4 Banner Health and Aetna Health Insurance Holding Company LLC is also 49% owned by Banner Health.

*5 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.

*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




* Aetna Life Insurance Company owns substantially all of the non-managing member interests of Aetna Partners Diversified Fund, LLC.

ANNUAL STATEMENT FOR THE YEAR 2018 OF THE Aetna Health Inc. (a Maine corporation)

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).

*2 Innovation Health Holdings, LLC is also 50% owned by Inova Health System Foundation.

*3 Texas Health + Aetna Health Insurance Holding Company LLC is also 50% owned by Texas Health Resources.

*4 Banner Health and Aetna Health Insurance Holding Company LLC is also 49% owned by Banner Health.

*5 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.

*6 Sutter Health and Aetna Insurance Holding Company LLC is also 50% owned by Sutter Health Plan Products Organization, LLC.

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Underwriting and Investment Exhibit Part 3 Line 25

	Claim Adjustment Expenses		3	4	5
	1	2			
	Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
2504. Interest expense		909	(5,992)		(5,083)
2597. Summary of remaining write-ins for Line 25 from overflow page	0	909	(5,992)	0	(5,083)

ALPHABETICAL INDEX

ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business 7

Assets 2

Cash Flow 6

Exhibit 1 - Enrollment By Product Type for Health Business Only 17

Exhibit 2 - Accident and Health Premiums Due and Unpaid 18

Exhibit 3 - Health Care Receivables 19

Exhibit 3A - Analysis of Health Care Receivables Collected and Accrued 20

Exhibit 4 - Claims Unpaid and Incentive Pool, Withhold and Bonus 21

Exhibit 5 - Amounts Due From Parent, Subsidiaries and Affiliates 22

Exhibit 6 - Amounts Due To Parent, Subsidiaries and Affiliates 23

Exhibit 7 - Part 1 - Summary of Transactions With Providers 24

Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries 24

Exhibit 8 - Furniture, Equipment and Supplies Owned 25

Exhibit of Capital Gains (Losses) 15

Exhibit of Net Investment Income 15

Exhibit of Nonadmitted Assets 16

Exhibit of Premiums, Enrollment and Utilization (State Page) 30

Five-Year Historical Data 29

General Interrogatories 27

Jurat Page 1

Liabilities, Capital and Surplus 3

Notes To Financial Statements 26

Overflow Page For Write-ins 44

Schedule A - Part 1 E01

Schedule A - Part 2 E02

Schedule A - Part 3 E03

Schedule A - Verification Between Years SI02

Schedule B - Part 1 E04

Schedule B - Part 2 E05

Schedule B - Part 3 E06

Schedule B - Verification Between Years SI02

Schedule BA - Part 1 E07

Schedule BA - Part 2 E08

Schedule BA - Part 3 E09

Schedule BA - Verification Between Years SI03

Schedule D - Part 1 E10

Schedule D - Part 1A - Section 1 SI05

Schedule D - Part 1A - Section 2 SI08

Schedule D - Part 2 - Section 1 E11

Schedule D - Part 2 - Section 2 E12

Schedule D - Part 3 E13

Schedule D - Part 4 E14

Schedule D - Part 5 E15

Schedule D - Part 6 - Section 1 E16

Schedule D - Part 6 - Section 2 E16

Schedule D - Summary By Country SI04

Schedule D - Verification Between Years SI03

Schedule DA - Part 1 E17

Schedule DA - Verification Between Years SI10

Schedule DB - Part A - Section 1 E18

Schedule DB - Part A - Section 2 E19

Schedule DB - Part A - Verification Between Years SI11

Schedule DB - Part B - Section 1 E20

Schedule DB - Part B - Section 2 E21

Schedule DB - Part B - Verification Between Years SI11

Schedule DB - Part C - Section 1 SI12

Schedule DB - Part C - Section 2 SI13

Schedule DB - Part D - Section 1 E22

Schedule DB - Part D - Section 2 E23

Schedule DB - Verification SI14

Schedule DL - Part 1 E24

Schedule DL - Part 2 E25

Schedule E - Part 1 - Cash E26

Schedule E - Part 2 - Cash Equivalents E27

Schedule E - Part 2 - Verification Between Years SI15

Schedule E - Part 3 - Special Deposits E28

ANNUAL STATEMENT BLANK (Continued)

Schedule S - Part 1 - Section 2	31
Schedule S - Part 2	32
Schedule S - Part 3 - Section 2	33
Schedule S - Part 4	34
Schedule S - Part 5	35
Schedule S - Part 6.....	36
Schedule S - Part 7.....	37
Schedule T - Part 2 - Interstate Compact	39
Schedule T - Premiums and Other Considerations	38
Schedule Y - Information Concerning Activities of Insurer Members of a Holding Company Group	40
Schedule Y - Part 1A - Detail of Insurance Holding Company System	41
Schedule Y - Part 2 - Summary of Insurer's Transactions With Any Affiliates	42
Statement of Revenue and Expenses	4
Summary Investment Schedule	SI01
Supplemental Exhibits and Schedules Interrogatories	43
Underwriting and Investment Exhibit - Part 1	8
Underwriting and Investment Exhibit - Part 2	9
Underwriting and Investment Exhibit - Part 2A	10
Underwriting and Investment Exhibit - Part 2B	11
Underwriting and Investment Exhibit - Part 2C	12
Underwriting and Investment Exhibit - Part 2D	13
Underwriting and Investment Exhibit - Part 3	14